A1cftm1c(EUCOMM)Hmgu/A1cftm1c(EUCOMM)Hmgu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6N * DBA
|
abnormal blood homeostasis |
J:281365
|
|
abnormal hepatobiliary system physiology |
J:281365
|
|
abnormal urine homeostasis |
J:281365
|
|
decreased circulating glucose level |
J:281365
|
|
decreased circulating insulin level |
J:281365
|
|
decreased circulating ketone body level |
J:281365
|
|
decreased fasting circulating glucose level |
J:281365
|
|
decreased liver triglyceride level |
J:281365
|
|
decreased liver weight |
J:281365
|
|
decreased susceptibility to diet-induced obesity |
J:281365
|
|
decreased urine uric acid level |
J:281365
|
|
normal
homeostasis/metabolism phenotype |
J:281365
|
|
impaired gluconeogenesis |
J:281365
|
|
improved glucose tolerance |
J:281365
|
|
increased circulating cholesterol level |
J:281365
|
|
increased circulating triglyceride level |
J:281365
|
|
increased insulin sensitivity |
J:281365
|
|
increased liver glycogen level |
J:281365
|
Abca1tm1Jp/Abca1+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * B6.Cg-Tg(Alb-cre)21Mgn/J
|
abnormal cholesterol homeostasis |
J:98093
|
|
abnormal circulating phospholipid level |
J:98093
|
|
decreased circulating cholesterol level |
J:98093
|
|
decreased circulating HDL cholesterol level |
J:98093
|
Abca1tm1Jp/Abca1tm1Jp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * B6.Cg-Tg(Alb-cre)21Mgn/J
|
abnormal cholesterol homeostasis |
J:98093
|
|
abnormal circulating phospholipid level |
J:98093
|
|
decreased circulating cholesterol level |
J:98093
|
|
decreased circulating HDL cholesterol level |
J:98093
|
|
decreased circulating LDL cholesterol level |
J:98093
|
|
increased circulating triglyceride level |
J:98093
|
Abca1tm1Jp/Abca1tm1Jp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * DBA
|
decreased circulating HDL cholesterol level |
J:107802
|
Abca1tm1Jp/Abca1tm1Jp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(Vil1-cre)997Gum/0
involves: 129S6/SvEvTac * C57BL/6 * DBA * SJL
|
decreased circulating HDL cholesterol level |
J:107802
|
Abcb4tm1Bor/Abcb4tm1Bor
Portm1Wolf/Portm1Wolf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA * FVB/N
|
abnormal bile salt homeostasis |
J:215915
|
|
bile duct proliferation |
J:215915
|
|
cholestasis |
J:215915
|
|
normal
growth/size/body region phenotype |
J:215915
|
|
increased bile salt level |
J:215915
|
|
increased circulating alanine transaminase level |
J:215915
|
|
increased circulating alkaline phosphatase level |
J:215915
|
|
increased circulating bilirubin level |
J:215915
|
|
increased hepatocyte proliferation |
J:215915
|
|
increased liver weight |
J:215915
|
|
liver fibrosis |
J:215915
|
Abcb7tm1Mdf/Y
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
either: B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn Abcb7tm1Mdf or (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA)
|
abnormal circulating enzyme level |
J:106838
|
|
abnormal enzyme/coenzyme activity |
J:106838
|
|
abnormal hepatocyte mitochondrial morphology |
J:106838
|
|
abnormal hepatocyte morphology |
J:106838
|
|
abnormal liver morphology |
J:106838
|
|
hemosiderosis |
J:106838
|
Abcc6tm1c(EUCOMM)Wtsi/Abcc6tm1c(EUCOMM)Wtsi
E2f1Tg(Wnt1-cre)2Sor/?
Speer6-ps1Tg(Alb-cre)21Mgn/?
B6.Cg-E2f1Tg(Wnt1-cre)2Sor Abcc6tm1c(EUCOMM)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn
|
abnormal snout skin morphology |
J:252837
|
|
calcified skin |
J:252837
|
|
calcinosis |
J:252837
|
Abcc6tm1c(EUCOMM)Wtsi/Abcc6tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/?
B6.Cg-Abcc6tm1c(EUCOMM)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn
|
abnormal snout skin morphology |
J:252837
|
|
calcified skin |
J:252837
|
|
calcinosis |
J:252837
|
Abcc6tm1c(EUCOMM)Wtsi/Abcc6tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/?
Tg(Cdx1-cre)23Kem/?
B6.Cg-Abcc6tm1c(EUCOMM)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn Tg(Cdx1-cre)23Kem
|
abnormal snout skin morphology |
J:252837
|
|
calcified skin |
J:252837
|
|
calcinosis |
J:252837
|
Abcg5tm1.1Hobb/Abcg5tm1.1Hobb
Abcg8tm1.1Hobb/Abcg8tm1.1Hobb
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: C57BL/6 * DBA * SJL
|
abnormal cellular cholesterol metabolism |
J:215443
|
|
abnormal feces composition |
J:215443
|
|
abnormal intestinal cholesterol absorption |
J:215443
|
|
abnormal phytosterol level |
J:215443
|
|
decreased cholesterol efflux |
J:215443
|
|
decreased circulating cholesterol level |
J:215443
|
|
decreased phytosterol level |
J:215443
|
|
increased cholesterol level |
J:215443
|
|
increased circulating phytosterol level |
J:215443
|
Abhd5tm1.1Lqyu/Abhd5tm1.1Lqyu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:199570
|
|
abnormal lipid level |
J:199570
|
|
abnormal liver morphology |
J:199570
|
|
abnormal liver physiology |
J:199570
|
|
abnormal phospholipid level |
J:199570
|
|
decreased fatty acid oxidation |
J:199570
|
|
decreased triglyceride lipase activity |
J:199570
|
|
enlarged liver |
J:199570
|
|
hepatic steatosis |
J:199570
|
|
normal
homeostasis/metabolism phenotype |
J:199570
|
|
increased circulating alanine transaminase level |
J:199570
|
|
increased circulating aspartate transaminase level |
J:199570
|
|
increased liver cholesterol level |
J:199570
|
|
increased liver free fatty acids level |
J:199570
|
|
increased liver triglyceride level |
J:199570
|
|
increased liver weight |
J:199570
|
|
liver fibrosis |
J:199570
|
|
liver inflammation |
J:199570
|
|
macrovesicular hepatic steatosis |
J:199570
|
|
microvesicular hepatic steatosis |
J:199570
|
|
oxidative stress |
J:199570
|
|
pale liver |
J:199570
|
Acacatm2Sjw/Acacatm2Sjw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S7/SvEvBrd * C57BL/6J * FVB
|
abnormal enzyme/coenzyme activity |
J:110200
|
|
abnormal glucose homeostasis |
J:110200
|
|
abnormal lipid level |
J:110200
|
|
abnormal liver physiology |
J:110200
|
|
decreased circulating free fatty acids level |
J:110200
|
|
decreased circulating ketone body level |
J:110200
|
|
decreased fatty acids level |
J:110200
|
|
decreased liver triglyceride level |
J:110200
|
|
decreased susceptibility to hepatic steatosis |
J:110200
|
|
hyperglycemia |
J:110200
|
|
increased circulating free fatty acids level |
J:110200
|
|
increased circulating insulin level |
J:110200
|
Acsl1tm1Rcol/Acsl1tm1Rcol
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal lipid homeostasis |
J:155714
|
|
normal
adipose tissue phenotype |
J:155714
|
|
normal
growth/size/body region phenotype |
J:155714
|
|
normal
homeostasis/metabolism phenotype |
J:155714
|
Adartm1Knk/Adartm1Knk
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
abnormal circulating enzyme level |
J:87714
|
|
abnormal liver morphology |
J:87714
|
|
decreased body size |
J:87714
|
|
normal
hematopoietic system phenotype |
J:87714
|
|
hyperglycemia |
J:87714
|
|
increased circulating alanine transaminase level |
J:87714
|
|
increased circulating alkaline phosphatase level |
J:87714
|
|
increased circulating aspartate transaminase level |
J:87714
|
|
increased circulating lactate dehydrogenase level |
J:87714
|
|
increased hepatocyte apoptosis |
J:87714
|
Adh5tm1.1Llli/Adh5tm1.1Llli
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Adh5tm1.1Llli Speer6-ps1Tg(Alb-cre)21Mgn
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:173666
|
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:173666
|
Agap2tm1Kye/Agap2tm1Kye
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA/2
|
abnormal gluconeogenesis |
J:174775
|
|
decreased circulating triglyceride level |
J:174775
|
|
decreased liver cholesterol level |
J:174775
|
|
decreased liver free fatty acids level |
J:174775
|
|
decreased liver triglyceride level |
J:174775
|
|
normal
growth/size/body region phenotype |
J:174775
|
|
normal
homeostasis/metabolism phenotype |
J:174775
|
|
hyperglycemia |
J:174775
|
|
impaired glucose tolerance |
J:174775
|
|
increased circulating insulin level |
J:174775
|
|
insulin resistance |
J:174775
|
Ahrb-1/Ahrb-1
Aiptm2.1Bra/Aiptm2.1Bra
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn Aiptm2.1Bra
|
abnormal circulating alanine transaminase level |
J:166864
|
|
decreased body size |
J:166864
|
|
decreased physiological sensitivity to xenobiotic |
J:166864
|
|
patent ductus venosus |
J:166864
|
Ahrtm3.1Bra/Ahrtm3.1Bra
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Ahrtm3.1Bra Speer6-ps1Tg(Alb-cre)21Mgn
|
normal
cardiovascular system phenotype |
J:104388
|
|
decreased physiological sensitivity to xenobiotic |
J:104388
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Ptentm1Hwu/Ptentm1Hwu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
abnormal liver morphology |
J:218587
|
|
decreased susceptibility to hepatic steatosis |
J:218587
|
|
hyperglycemia |
J:160759
|
|
impaired glucose tolerance |
J:160759
|
|
increased tumor latency |
J:218587
|
|
normal
liver/biliary system phenotype |
J:160759
|
Antxr2tm1.1Lepp/Antxr2tm1.1Lepp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * SJL
|
normal
mortality/aging |
J:150952
|
Apoetm1Unc/Apoetm1Unc
Smarcd1tm1.1Jddl/Smarcd1tm1.1Jddl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal bile salt homeostasis |
J:228944
|
|
decreased circulating cholesterol level |
J:228944
|
|
decreased susceptibility to atherosclerosis |
J:228944
|
Aqp11tm1.1Nlsn/Aqp11tm1.1Nlsn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * C57BL/6 * DBA
|
abnormal endoplasmic reticulum morphology |
J:194939
|
|
abnormal hepatocyte morphology |
J:194939
|
|
decreased blood urea nitrogen level |
J:194939
|
|
decreased circulating free fatty acids level |
J:194939
|
|
decreased circulating glycerol level |
J:194939
|
|
decreased circulating ketone body level |
J:194939
|
|
decreased circulating triglyceride level |
J:194939
|
|
normal
homeostasis/metabolism phenotype |
J:194939
|
|
increased circulating aspartate transaminase level |
J:194939
|
|
increased circulating HDL cholesterol level |
J:194939
|
Arnttm1Bra/Arnttm1Bra
Vhltm1Jae/Vhltm1Jae
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * BALB/c * C57BL/6 * DBA
|
normal
liver/biliary system phenotype |
J:97652
|
Atp8b1tm1Nbf/Atp8b1tm1Nbf
Portm1Wolf/Portm1Wolf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
abnormal bile salt homeostasis |
J:215915
|
|
abnormal bile secretion |
J:215915
|
|
bile duct proliferation |
J:215915
|
|
cholestasis |
J:215915
|
|
increased bile salt level |
J:215915
|
|
increased circulating alanine transaminase level |
J:215915
|
|
increased circulating alkaline phosphatase level |
J:215915
|
|
increased circulating bilirubin level |
J:215915
|
|
increased liver weight |
J:215915
|
|
increased susceptibility to induced morbidity/mortality |
J:215915
|
|
weight loss |
J:215915
|
Blvratm1c(EUCOMM)Hmgu/Blvratm1c(EUCOMM)Hmgu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6J * C57BL/6N
|
decreased fatty acid beta-oxidation |
J:237631
|
|
decreased liver glycogen level |
J:237631
|
|
hepatic steatosis |
J:237631
|
|
impaired glucose tolerance |
J:237631
|
|
increased circulating insulin level |
J:237631
|
|
increased fasting circulating glucose level |
J:237631
|
|
increased fatty acids level |
J:237631
|
|
increased liver triglyceride level |
J:237631
|
|
insulin resistance |
J:237631
|
Bmal1tm1.1Shbi/Bmal1tm1.1Shbi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6J * DBA
|
normal
behavior/neurological phenotype |
J:177865
|
|
normal
liver/biliary system phenotype |
J:177865
|
Bub1btm1Jvd/Bub1btm1Jvd
Mad2l1bptm1.1Itl/Mad2l1bptm1.1Itl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * FVB
|
abnormal hepatocyte morphology |
J:234643
|
|
decreased body weight |
J:234643
|
|
hypoglycemia |
J:234643
|
|
improved glucose tolerance |
J:234643
|
|
increased hepatocyte karyomegaly |
J:234643
|
|
increased insulin sensitivity |
J:234643
|
|
polyploidy |
J:234643
|
|
postnatal growth retardation |
J:234643
|
|
preweaning lethality, incomplete penetrance |
J:234643
|
Cav1tm1Pesch/Cav1tm1Pesch
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
FVB.Cg-Cav1tm1Pesch Speer6-ps1Tg(Alb-cre)21Mgn
|
decreased circulating glucose level |
J:182288
|
|
decreased circulating glycerol level |
J:182288
|
|
normal
liver/biliary system phenotype |
J:182288
|
Ccl2tm1.1Pame/Ccl2tm1.1Pame
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
normal
immune system phenotype |
J:171379
|
Ccn1tm3.1Lfl/Ccn1tm3.1Lfl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
|
abnormal cellular replicative senescence |
J:204032
|
|
increased susceptibility to injury |
J:204032
|
|
liver fibrosis |
J:204032
|
|
normal
liver/biliary system phenotype |
J:204032
|
Ccn2tm1.1Alea/Ccn2tm1.1Alea
Mob1atm1.1Asuz/Mob1atm1.1Asuz
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA
|
abnormal cholangiocyte morphology |
J:228499
|
|
increased liver weight |
J:228499
|
|
liver fibrosis |
J:228499
|
Cdk1tm2.1Kald/Cdk1tm2.1Kald
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6 * DBA * SJL
|
abnormal hepatocyte morphology |
J:182141
|
|
abnormal mitosis |
J:182141
|
|
abnormal response to injury |
J:182141
|
|
decreased hepatocyte number |
J:182141
|
|
decreased hepatocyte proliferation |
J:182141
|
|
decreased incidence of induced tumors |
J:182141
|
|
polyploidy |
J:182141
|
Cdk5rap3tm1c(EUCOMM)Hmgu/Cdk5rap3tm1c(EUCOMM)Hmgu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJaeSor * C57BL/6N * DBA
|
normal
liver/biliary system phenotype |
J:272566
|
|
normal
mortality/aging |
J:272566
|
Cdo1tm1Mhst/Cdo1tm1Mhst
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal blood homeostasis |
J:186922
|
|
abnormal homeostasis |
J:186922
|
|
decreased circulating cysteine level |
J:186922
|
|
decreased cysteine level |
J:186922
|
Chrm3tm2.1Jwe/Chrm3tm2.1Jwe
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * DBA * FVB/N
|
decreased circulating glucose level |
J:158245
|
|
normal
growth/size/body region phenotype |
J:158245
|
|
normal
homeostasis/metabolism phenotype |
J:158245
|
Clk2tm1.1Ppgr/Clk2tm1.1Ppgr
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6NTac * FVB/N
|
abnormal fatty acid oxidation |
J:229283
|
|
decreased liver triglyceride level |
J:229283
|
|
decreased respiratory quotient |
J:229283
|
Cluhtm1.1Eir/Cluhtm1.1Eir
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: BALB/cJ * C57BL/6 * DBA * SJL
|
abnormal cellular respiration |
J:249661
|
|
abnormal circulating amino acid level |
J:249661
|
|
abnormal hepatocyte mitochondrial morphology |
J:249661
|
|
abnormal homeostasis |
J:249661
|
|
abnormal liver physiology |
J:249661
|
|
decreased fasting circulating glucose level |
J:249661
|
|
hypoglycemia |
J:249661
|
|
increased apoptosis |
J:249661
|
|
increased brown fat lipid droplet number |
J:249661
|
|
increased circulating alanine transaminase level |
J:249661
|
|
increased circulating lysine level |
J:249661
|
|
increased circulating methionine level |
J:249661
|
|
increased circulating proline level |
J:249661
|
|
increased circulating serine level |
J:249661
|
|
increased circulating threonine level |
J:249661
|
|
normal
liver/biliary system phenotype |
J:249661
|
Commd1tm2.1Bvds/Commd1tm2.1Bvds
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEv * C57BL/6 * DBA * SJL
|
increased liver copper level |
J:182331
|
Coq7tm1Hek/Coq7tm2Hek
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6NTac
|
abnormal liver physiology |
J:202240
|
|
abnormal respiratory electron transport chain |
J:202240
|
|
normal
liver/biliary system phenotype |
J:202240
|
|
normal
mortality/aging |
J:202240
|
Creg1em1Yal/Creg1em1Yal
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal circulating enzyme level |
J:263073
|
|
abnormal glucose homeostasis |
J:263073
|
|
abnormal lipid homeostasis |
J:263073
|
|
decreased glycogen level |
J:263073
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:263073
|
|
impaired glucose tolerance |
J:263073
|
|
increased body weight |
J:263073
|
|
increased circulating alanine transaminase level |
J:263073
|
|
increased circulating alkaline phosphatase level |
J:263073
|
|
increased circulating aspartate transaminase level |
J:263073
|
|
increased circulating insulin level |
J:263073
|
|
increased fasting circulating glucose level |
J:263073
|
|
increased liver cholesterol level |
J:263073
|
|
increased liver free fatty acids level |
J:263073
|
|
increased liver weight |
J:263073
|
|
insulin resistance |
J:263073
|
Cul4atm1.1Pra/Cul4atm1.1Pra
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6NTac * DBA
|
decreased body weight |
J:172043
|
|
decreased hepatocyte proliferation |
J:172043
|
|
increased susceptibility to injury |
J:172043
|
Cyb5atm1Wolf/Cyb5atm1Wolf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal xenobiotic pharmacokinetics |
J:143097
|
|
normal
liver/biliary system phenotype |
J:143097
|
Dbitm2.1Smdp/Dbitm2.2Smdp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA * FVB/N
|
no abnormal phenotype detected |
J:204137
|
Ddit3tm1.1Irt/Ddit3tm1.1Irt
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(Mup3-Plau)350-2Eps/?
involves: C57BL/6 * DBA
|
increased hepatocellular carcinoma incidence |
J:233146
|
Deptortm1.1Mala/Deptortm1.1Mala
Speer6-ps1Tg(Alb-cre)21Mgn/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 x DBA
|
decreased fasting circulating glucose level |
J:275931
|
|
decreased liver glycogen level |
J:275931
|
|
normal
growth/size/body region phenotype |
J:275931
|
|
normal
homeostasis/metabolism phenotype |
J:275931
|
|
increased insulin sensitivity |
J:275931
|
|
normal
liver/biliary system phenotype |
J:275931
|
Derl2tm1.1Hpl/Derl2tm1.1Hpl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
normal
liver/biliary system phenotype |
J:170650
|
Dhcr7tm1.1Sbpa/Dhcr7tm1.1Sbpa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Dhcr7tm1.1Sbpa Speer6-ps1Tg(Alb-cre)21Mgn
|
abnormal bile composition |
J:303316
|
|
abnormal bile salt homeostasis |
J:303316
|
|
abnormal sterol level |
J:303316
|
|
decreased lean body mass |
J:303316
|
|
decreased liver cholesterol level |
J:303316
|
|
normal
growth/size/body region phenotype |
J:303316
|
|
normal
homeostasis/metabolism phenotype |
J:303316
|
|
increased bile salt level |
J:303316
|
Dhcr24tm1c(EUCOMM)Wtsi/Dhcr24tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Dhcr24tm1c(EUCOMM)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn
|
abnormal bile composition |
J:304449
|
|
abnormal feces composition |
J:304449
|
|
abnormal liver morphology |
J:304449
|
|
abnormal sterol level |
J:304449
|
|
decreased liver cholesterol level |
J:304449
|
Dio3tm1Dmst/Dio3tm1Dmst
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal response to injury |
J:218350
|
|
normal
growth/size/body region phenotype |
J:218350
|
|
normal
homeostasis/metabolism phenotype |
J:218350
|
|
increased circulating thyroxine level |
J:218350
|
|
increased circulating triiodothyronine level |
J:218350
|
|
increased hepatocyte proliferation |
J:218350
|
|
normal
liver/biliary system phenotype |
J:218350
|
Dusp26em1Jhxia/Dusp26em1Jhxia
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal liver morphology |
J:279111
|
|
decreased liver glycogen level |
J:279111
|
|
impaired glucose tolerance |
J:279111
|
|
increased circulating alanine transaminase level |
J:279111
|
|
increased circulating aspartate transaminase level |
J:279111
|
|
increased circulating glucose level |
J:279111
|
|
increased fasting circulating glucose level |
J:279111
|
|
increased liver cholesterol level |
J:279111
|
|
increased liver free fatty acids level |
J:279111
|
|
increased liver triglyceride level |
J:279111
|
|
increased liver weight |
J:279111
|
|
increased susceptibility to diet-induced obesity |
J:279111
|
|
insulin resistance |
J:279111
|
|
liver fibrosis |
J:279111
|
Ei24tm1Hzha/Ei24tm1Hzha
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
abnormal hepatocyte mitochondrial morphology |
J:193420
|
|
abnormal hepatocyte morphology |
J:193420
|
|
abnormal liver lobule morphology |
J:193420
|
|
abnormal liver morphology |
J:193420
|
|
enlarged liver |
J:193420
|
|
impaired autophagy |
J:193420
|
Ern1tm1Rjk/Ern1tm2.1Rjk
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
abnormal apolipoprotein level |
J:171230
|
|
abnormal hepatocyte morphology |
J:171230
|
|
abnormal lipid level |
J:171230
|
|
decreased circulating cholesterol level |
J:171230
|
|
hepatic steatosis |
J:171230
|
|
increased hepatocyte apoptosis |
J:171230
|
|
increased liver triglyceride level |
J:171230
|
Faf2tm1Tfji/Faf2tm1Tfji
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * CBA * DBA
|
abnormal apolipoprotein level |
J:235325
|
|
decreased body weight |
J:235325
|
|
decreased circulating free fatty acids level |
J:235325
|
|
decreased circulating phospholipid level |
J:235325
|
|
decreased circulating triglyceride level |
J:235325
|
|
decreased circulating VLDL triglyceride level |
J:235325
|
|
normal
homeostasis/metabolism phenotype |
J:235325
|
|
increased circulating alkaline phosphatase level |
J:235325
|
|
increased circulating aspartate transaminase level |
J:235325
|
|
increased circulating phospholipid level |
J:235325
|
|
macrovesicular hepatic steatosis |
J:235325
|
Fasntm1Sem/Fasntm1Sem
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: 129X1/SvJ * C57BL/6 * DBA
|
abnormal blood homeostasis |
J:127793
|
|
decreased circulating cholesterol level |
J:127793
|
|
decreased circulating glucose level |
J:127793
|
|
decreased circulating insulin level |
J:127793
|
|
decreased liver cholesterol level |
J:127793
|
|
decreased saturated fatty acids level |
J:127793
|
|
decreased total body fat amount |
J:127793
|
|
decreased total fat pad weight |
J:127793
|
|
hepatic steatosis |
J:127793
|
|
increased circulating free fatty acids level |
J:127793
|
|
increased circulating glucagon level |
J:127793
|
|
increased liver weight |
J:127793
|
|
increased triglyceride level |
J:127793
|
Fbxl5tm2.1Kei/Fbxl5tm2.1Kei
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal blood coagulation |
J:176655
|
|
abnormal circulating enzyme level |
J:176655
|
|
abnormal hepatocyte mitochondrial morphology |
J:176655
|
|
abnormal hepatocyte morphology |
J:176655
|
|
abnormal liver physiology |
J:176655
|
|
decreased circulating unsaturated transferrin level |
J:176655
|
|
hepatic steatosis |
J:176655
|
|
increased circulating alanine transaminase level |
J:176655
|
|
increased circulating aspartate transaminase level |
J:176655
|
|
increased circulating iron level |
J:176655
|
|
increased circulating lactate dehydrogenase level |
J:176655
|
|
increased liver iron level |
J:176655
|
|
increased partial thromboplastin time |
J:176655
|
|
increased prothrombin time |
J:176655
|
|
increased susceptibility to induced morbidity/mortality |
J:176655
|
|
liver failure |
J:176655
|
|
liver hemorrhage |
J:176655
|
|
liver inflammation |
J:176655
|
|
pale liver |
J:176655
|
Fbxw7tm1Iken/Fbxw7+
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA
|
bile duct hyperplasia |
J:258194
|
|
dilated bile duct |
J:258194
|
Fbxw7tm1Iken/Fbxw7tm1Iken
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA
|
increased cholangiocarcinoma incidence |
J:258194
|
Fbxw7tm1Iken/Fbxw7tm1Iken
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * DBA
|
bile duct hyperplasia |
J:258194
|
|
dilated bile duct |
J:258194
|
Foxa2tm1Khk/Foxa2tm1Khk
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA
|
no abnormal phenotype detected |
J:63039
|
Foxm1tm1Rhc/Foxm1tm1Rhc
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129X1/SvJ * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:81015,
J:89472
|
|
abnormal liver regeneration |
J:81015
|
|
decreased incidence of tumors by chemical induction |
J:89472
|
|
decreased liver tumor incidence |
J:89472
|
Foxo1tm1Rdp/Foxo1tm1Rdp
Irs1tm1Mfw/Irs1tm1Mfw
Irs2tm2Mfw/Irs2tm2Mfw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA * FVB
|
abnormal triglyceride level |
J:137845
|
|
decreased circulating cholesterol level |
J:137845
|
|
decreased circulating free fatty acids level |
J:137845
|
|
decreased circulating HDL cholesterol level |
J:137845
|
|
decreased circulating triglyceride level |
J:137845
|
|
normal
homeostasis/metabolism phenotype |
J:137845
|
Foxo1tm1Rdp/Foxo1tm1Rdp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * C57BL/6 * DBA * FVB
|
improved glucose tolerance |
J:137845
|
Gab1tm1Gsf/Gab1tm1Gsf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal glucose homeostasis |
J:98318
|
|
abnormal lipid homeostasis |
J:98318
|
|
decreased circulating free fatty acids level |
J:98318
|
|
decreased circulating glucose level |
J:98318
|
|
decreased circulating insulin level |
J:98318
|
|
decreased circulating triglyceride level |
J:98318
|
|
decreased glycogen level |
J:98318
|
|
improved glucose tolerance |
J:98318
|
|
increased insulin sensitivity |
J:98318
|
Gaktm2Legr/Gaktm2Legr
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * DBA
|
abnormal bile duct morphology |
J:180119
|
|
abnormal hepatoblast differentiation |
J:180119
|
|
abnormal liver morphology |
J:180119
|
|
decreased body size |
J:180119
|
|
decreased liver glycogen level |
J:180119
|
|
increased body weight |
J:180119
|
|
jaundice |
J:180119
|
|
postnatal lethality, complete penetrance |
J:180119
|
Gcgrtm2.1Mjch/Gcgrtm2.1Mjch
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA * SJL
|
abnormal glucose homeostasis |
J:208604
|
|
decreased circulating glucose level |
J:208604
|
|
decreased circulating insulin level |
J:208604
|
|
hypoglycemia |
J:208604
|
|
improved glucose tolerance |
J:208604
|
|
increased bile salt level |
J:208604
|
|
increased circulating glucagon level |
J:208604
|
|
increased insulin sensitivity |
J:208604
|
|
increased pancreas weight |
J:208604
|
|
increased pancreatic alpha cell number |
J:208604
|
|
increased pancreatic alpha cell proliferation |
J:208604
|
|
increased pancreatic beta cell mass |
J:208604
|
Gcktm1.1Mgn/Gcktm1.1Mgn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * DBA/2
|
abnormal glucose homeostasis |
J:51826
|
|
decreased glycogen level |
J:51826
|
|
decreased insulin secretion |
J:51826
|
|
impaired glucose tolerance |
J:51826
|
|
increased circulating glucose level |
J:51826
|
|
increased circulating insulin level |
J:51826
|
|
insulin resistance |
J:51826
|
Gcktm1Hrt/Gck+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal heart echocardiography feature |
J:250069
|
|
abnormal mitochondrial crista morphology |
J:250069
|
|
abnormal pancreatic beta cell physiology |
J:250069
|
|
cardiac fibrosis |
J:250069
|
|
impaired glucose tolerance |
J:105247,
J:250069
|
|
increased circulating glucose level |
J:105247
|
|
increased fasting circulating glucose level |
J:250069
|
|
increased mitochondrial number |
J:250069
|
|
insulin resistance |
J:250069
|
|
prolonged PR interval |
J:250069
|
|
prolonged QRS complex duration |
J:250069
|
Gclctm1Tdal/Gclctm1Tdal
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * DBA
|
abnormal endoplasmic reticulum morphology |
J:202376
|
|
abnormal homeostasis |
J:202376
|
|
abnormal liver morphology |
J:202376
|
|
abnormal mitochondrial morphology |
J:202376
|
|
abnormal mitochondrial physiology |
J:202376
|
|
decreased mitochondrial number |
J:202376
|
|
hepatic steatosis |
J:202376
|
|
increased circulating alanine transaminase level |
J:202376
|
|
increased circulating aspartate transaminase level |
J:202376
|
|
postnatal growth retardation |
J:202376
|
|
premature death |
J:202376
|
Gfertm1.1Crg/Gfertm1.1Crg
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6 * DBA
|
abnormal cellular respiration |
J:227242
|
|
abnormal endoplasmic reticulum morphology |
J:227242
|
|
abnormal hepatocyte mitochondrial morphology |
J:227242
|
|
abnormal liver morphology |
J:227242
|
|
abnormal liver physiology |
J:227242
|
|
abnormal mitochondrial crista morphology |
J:227242
|
|
abnormal mitochondrial shape |
J:227242
|
|
abnormal oval cell physiology |
J:227242
|
|
decreased body weight |
J:227242
|
|
decreased liver cholesterol level |
J:227242
|
|
decreased mitochondrial number |
J:227242
|
|
dilated mitochondrion |
J:227242
|
|
focal hepatic necrosis |
J:227242
|
|
hepatic necrosis |
J:227242
|
|
hepatic steatosis |
J:227242
|
|
increased circulating alanine transaminase level |
J:227242
|
|
increased hepatocellular carcinoma incidence |
J:227242
|
|
increased hepatocyte apoptosis |
J:227242
|
|
increased hepatocyte proliferation |
J:227242
|
|
increased liver cholesterol level |
J:227242
|
|
increased liver triglyceride level |
J:227242
|
|
increased liver weight |
J:227242
|
|
liver fibrosis |
J:227242
|
|
liver inflammation |
J:227242
|
|
macrovesicular hepatic steatosis |
J:227242
|
|
microvesicular hepatic steatosis |
J:227242
|
|
pale liver |
J:227242
|
Ggcxtm1Sinos/Ggcx+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Ggcxtm1Sinos Speer6-ps1Tg(Alb-cre)21Mgn
|
normal
mortality/aging |
J:212951
|
Ggcxtm1Sinos/Ggcxtm1Sinos
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Ggcxtm1Sinos Speer6-ps1Tg(Alb-cre)21Mgn
|
anemia |
J:212951
|
|
impaired blood coagulation |
J:212951
|
|
increased bleeding time |
J:212951
|
|
pregnancy-related premature death |
J:212951
|
|
premature death |
J:212951
|
|
subcutaneous hemorrhage |
J:212951
|
|
uterine hemorrhage |
J:212951
|
|
vaginal hemorrhage |
J:212951
|
Ghrtm1.1Masp/Ghrtm1.1Masp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJaeSor * C57BL/6 * DBA
|
decreased bone mineral density |
J:152627
|
|
decreased circulating insulin-like growth factor I level |
J:152627
|
|
decreased circulating triglyceride level |
J:152627
|
|
decreased kidney weight |
J:152627
|
|
decreased liver triglyceride level |
J:152627
|
|
hepatic steatosis |
J:152627
|
|
impaired glucose tolerance |
J:152627
|
|
increased circulating free fatty acids level |
J:152627
|
|
increased circulating growth hormone level |
J:152627
|
|
increased circulating insulin level |
J:152627
|
|
increased liver weight |
J:152627
|
Glultm1.1Geno/Glultm1.1Geno
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6J * DBA
|
abnormal fear-related response |
J:221031
|
|
normal
homeostasis/metabolism phenotype |
J:221031
|
|
hyperactivity |
J:221031
|
|
increased circulating ammonia level |
J:221031
|
|
normal
liver/biliary system phenotype |
J:221031
|
|
oxidative stress |
J:221031
|
|
premature death |
J:221031
|
Gpcpd1tm1c(EUCOMM)Hmgu/Gpcpd1tm1c(EUCOMM)Hmgu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
normal
homeostasis/metabolism phenotype |
J:345630
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(tetO-Xbp1_is)#Pesch/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA * FVB
|
abnormal glucose homeostasis |
J:194290
|
|
abnormal liver morphology |
J:194290
|
|
decreased circulating insulin level |
J:194290
|
|
decreased fasting circulating glucose level |
J:194290
|
|
decreased liver glycogen level |
J:194290
|
|
decreased total body fat amount |
J:194290
|
|
enhanced lipolysis |
J:194290
|
|
hepatic steatosis |
J:194290
|
|
hypoglycemia |
J:194290
|
|
increased circulating free fatty acids level |
J:194290
|
|
increased insulin sensitivity |
J:194290
|
|
increased liver triglyceride level |
J:194290
|
|
increased respiratory quotient |
J:194290
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
TgTn(sb-T2/Onc)68Dla/0
involves: C57BL/6 * DBA/2 * FVB/N
|
abnormal liver morphology |
J:147264
|
|
increased hepatocellular carcinoma incidence |
J:147264
|
|
increased liver adenoma incidence |
J:147264
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Trp53tm3Tyj/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
TgTn(sb-T2/Onc)68Dla/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
|
abnormal liver morphology |
J:147264
|
|
increased hepatocellular carcinoma incidence |
J:147264
|
|
increased liver adenoma incidence |
J:147264
|
Gt(ROSA)26Sortm2Bet/Gt(ROSA)26Sortm2Bet
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: BALB/c * C57BL/6 * DBA
|
abnormal bile duct development |
J:174261
|
|
abnormal bile duct morphology |
J:174261
|
|
abnormal intrahepatic bile duct morphology |
J:174261
|
|
abnormal liver morphology |
J:174261
|
|
decreased hepatocyte number |
J:174261
|
|
increased hepatocyte proliferation |
J:174261
|
|
increased liver weight |
J:174261
|
Gt(ROSA)26Sortm3(HIF1A*)Kael/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:144666
|
|
microvesicular hepatic steatosis |
J:144666
|
|
normal
mortality/aging |
J:144666
|
Gt(ROSA)26Sortm3(HIF1A*)Kael/Gt(ROSA)26Sortm4(HIF2A*)Kael
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * DBA
|
abnormal blood vessel morphology |
J:144666
|
|
abnormal liver morphology |
J:144666
|
|
normal
growth/size/body region phenotype |
J:144666
|
|
hepatic steatosis |
J:144666
|
|
increased hematocrit |
J:144666
|
|
increased hepatocyte proliferation |
J:144666
|
|
increased liver weight |
J:144666
|
|
premature death |
J:144666
|
|
reddish skin |
J:144666
|
|
reticulocytosis |
J:144666
|
Gt(ROSA)26Sortm4(HIF2A*)Kael/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * DBA
|
abnormal blood vessel morphology |
J:144666
|
|
abnormal liver morphology |
J:144666
|
|
normal
growth/size/body region phenotype |
J:144666
|
|
hepatic steatosis |
J:144666
|
|
increased hematocrit |
J:144666
|
|
increased hepatocyte proliferation |
J:144666
|
|
increased liver weight |
J:144666
|
|
premature death |
J:144666
|
|
reddish skin |
J:144666
|
|
reticulocytosis |
J:144666
|
Gys2tm1.1Pro/Gys2tm1.1Pro
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA
|
abnormal circulating ketone body level |
J:162043
|
|
abnormal gluconeogenesis |
J:162043
|
|
abnormal glucose homeostasis |
J:162043
|
|
abnormal triglyceride level |
J:162043
|
|
decreased cardiac muscle cell glucose uptake |
J:162043
|
|
decreased circulating glucose level |
J:162043
|
|
decreased circulating insulin level |
J:162043
|
|
decreased glycogen catabolism rate |
J:162043
|
|
decreased glycogen level |
J:162043
|
|
decreased heart weight |
J:162043
|
|
decreased liver weight |
J:162043
|
|
decreased systemic arterial diastolic blood pressure |
J:162043
|
|
impaired exercise endurance |
J:162043
|
|
impaired glucose tolerance |
J:162043
|
|
increased liver triglyceride level |
J:162043
|
Hdac3tm1Swh/Hdac3tm1.1Swh
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * DBA
|
abnormal glucose homeostasis |
J:134288
|
|
abnormal hepatocyte morphology |
J:134288
|
|
decreased body size |
J:134288
|
|
decreased circulating glucagon level |
J:134288
|
|
decreased circulating insulin level |
J:134288
|
|
decreased liver glycogen level |
J:134288
|
|
decreased total body fat amount |
J:134288
|
|
enlarged liver |
J:134288
|
|
hepatic steatosis |
J:134288
|
|
hypoglycemia |
J:134288
|
|
increased cholesterol level |
J:134288
|
|
increased circulating alanine transaminase level |
J:134288
|
|
increased circulating cholesterol level |
J:134288
|
|
increased circulating LDL cholesterol level |
J:134288
|
|
increased circulating triglyceride level |
J:134288
|
|
increased hepatocyte proliferation |
J:134288
|
|
increased liver triglyceride level |
J:134288
|
|
increased liver weight |
J:134288
|
|
normal
mortality/aging |
J:134288
|
|
pale liver |
J:134288
|
Hif1atm3Rsjo/Hif1atm3Rsjo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1Tg(Alb-cre)21Mgn
B6.Cg-Hif1atm3Rsjo Speer6-ps1Tg(Alb-cre)21Mgn
|
decreased physiological sensitivity to xenobiotic |
J:211093
|
|
normal
vision/eye phenotype |
J:211093
|
Hif1atm3Rsjo/Hif1atm3Rsjo
Vhltm1Jae/Vhltm1Jae
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * BALB/c * C57BL/6 * DBA
|
abnormal vasodilation |
J:97652
|
|
hepatic steatosis |
J:97652
|
|
increased vascular endothelial cell number |
J:97652
|
Hif1antm1.1Rsjo/Hif1antm1.1Rsjo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6 * DBA
|
no abnormal phenotype detected |
J:160941
|
Hjvtm1Kpan/Hjvtm1Kpan
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6
|
abnormal iron homeostasis |
J:231428
|
|
abnormal macrophage morphology |
J:231428
|
|
decreased circulating unsaturated transferrin level |
J:231428
|
|
decreased spleen iron level |
J:231428
|
|
hemochromatosis |
J:231428
|
|
increased circulating ferritin level |
J:231428
|
|
increased circulating iron level |
J:231428
|
|
increased liver iron level |
J:231428
|
Hmgb1tm1.1Ttg/Hmgb1tm1.1Ttg
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
increased circulating interleukin-1 beta level |
J:205499
|
|
increased circulating interleukin-18 level |
J:205499
|
Hmgcltm2Gam/Hmgcltm2Gam
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Hmgcltm2Gam Speer6-ps1Tg(Alb-cre)21Mgn
|
abnormal gluconeogenesis |
J:204294
|
|
abnormal hepatocyte mitochondrial morphology |
J:204294
|
|
abnormal hepatocyte physiology |
J:204294
|
|
normal
homeostasis/metabolism phenotype |
J:204294
|
|
hypoglycemia |
J:204294
|
|
increased circulating ammonia level |
J:204294
|
|
increased circulating carnitine level |
J:204294
|
|
lethargy |
J:204294
|
|
premature death |
J:204294
|
Hmgcrem1Bcgen/Hmgcrem1Bcgen
Usp20em1Gpt/Usp20em1Gpt
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6JGpt * DBA
|
normal
homeostasis/metabolism phenotype |
J:299971
|
|
increased circulating triglyceride level |
J:299971
|
Hmox1tm1.1Hes/Hmox1tm1.1Hes
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA
|
abnormal cellular respiration |
J:214639
|
|
abnormal metabolism |
J:214639
|
|
abnormal mitochondrial physiology |
J:214639
|
|
abnormal redox activity |
J:214639
|
|
decreased circulating alanine transaminase level |
J:214639
|
|
decreased circulating aspartate transaminase level |
J:214639
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:214639
|
|
increased insulin sensitivity |
J:214639
|
Hnf1atm1.1Ylee/Hnf1atm2Ylee
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: 129X1/SvJ * C57BL/6 * DBA
|
decreased circulating insulin level |
J:81639
|
|
normal
growth/size/body region phenotype |
J:81639
|
|
normal
homeostasis/metabolism phenotype |
J:81639
|
|
hyperglycemia |
J:81639
|
|
normal
reproductive system phenotype |
J:81639
|
Hs2st1tm1.1Je/Hs2st1tm1.1Je
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Hs2st1tm1.1Je Speer6-ps1Tg(Alb-cre)21Mgn
|
abnormal hepatocyte physiology |
J:158299
|
|
abnormal lipid homeostasis |
J:158299
|
|
increased circulating triglyceride level |
J:158299
|
Hs6st1tm1Wvc/Hs6st1tm1Wvc
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * DBA
|
normal
homeostasis/metabolism phenotype |
J:158299
|
Hsd11b1tm1Ggla/Hsd11b1tm1Ggla
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal eating behavior |
J:189059
|
|
abnormal glucose tolerance |
J:189059
|
|
decreased circulating corticosterone level |
J:189059
|
|
decreased circulating insulin level |
J:189059
|
|
enlarged adrenal glands |
J:189059
|
|
normal
growth/size/body region phenotype |
J:189059
|
|
normal
homeostasis/metabolism phenotype |
J:189059
|
|
increased circulating HDL cholesterol level |
J:189059
|
|
normal
liver/biliary system phenotype |
J:189059
|
Igf2rtm1Rlj/Igf2r+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129/Sv * C57BL/6 * DBA
|
genetic imprinting |
J:80932
|
|
normal
liver/biliary system phenotype |
J:80932
|
|
no abnormal phenotype detected |
J:80932
|
Il6ratm1.1Drew/Il6ratm1.1Drew
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * SJL
|
decreased acute inflammation |
J:160966
|
|
normal
homeostasis/metabolism phenotype |
J:160966
|
Il7tm2.1Iku/Il7tm2.1Iku
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA
|
abnormal B cell differentiation |
J:190615
|
|
abnormal NK T cell physiology |
J:190615
|
|
decreased B cell number |
J:190615
|
|
decreased double-negative T cell number |
J:190615
|
|
decreased lymphocyte cell number |
J:190615
|
|
decreased NK T cell number |
J:190615
|
|
decreased T cell number |
J:190615
|
|
normal
hematopoietic system phenotype |
J:190615
|
|
normal
immune system phenotype |
J:190615
|
Insrtm1Khn/Insrtm1Khn
Pdx1tm1Ted/Pdx1+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
decreased pancreatic beta cell mass |
J:92861
|
Insrtm1Khn/Insrtm1Khn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
abnormal enzyme/coenzyme activity |
J:234643
|
|
abnormal hepatocyte physiology |
J:234643
|
|
abnormal liver morphology |
J:234643
|
|
abnormal liver physiology |
J:234643
|
|
decreased liver glycogen level |
J:234643
|
|
hyperglycemia |
J:234643
|
|
impaired glucose tolerance |
J:234643
|
|
increased circulating insulin level |
J:234643
|
|
insulin resistance |
J:234643
|
Insrtm1Khn/Insrtm1Khn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
decreased circulating glucose level |
J:121640
|
|
hyperglycemia |
J:121640
|
|
impaired glucose tolerance |
J:121640
|
|
increased circulating insulin level |
J:121640
|
|
increased pancreatic beta cell mass |
J:121640
|
|
insulin resistance |
J:121640
|
Insrtm1Khn/Insrtm1Khn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6J * DBA/2 * FVB
|
abnormal circulating serum albumin level |
J:63878
|
|
abnormal glucose homeostasis |
J:63878
|
|
abnormal hepatocyte morphology |
J:63878
|
|
abnormal insulin clearance |
J:63878
|
|
abnormal lipid homeostasis |
J:63878
|
|
abnormal liver morphology |
J:63878
|
|
abnormal liver physiology |
J:63878
|
|
decreased circulating free fatty acids level |
J:63878
|
|
decreased circulating triglyceride level |
J:63878
|
|
enlarged gallbladder |
J:63878
|
|
hyperglycemia |
J:63878
|
|
impaired glucose tolerance |
J:63878
|
|
increased bile salt level |
J:92861
|
|
increased circulating alkaline phosphatase level |
J:63878
|
|
increased circulating aspartate transaminase level |
J:63878
|
|
increased circulating insulin level |
J:63878
|
|
increased insulin secretion |
J:63878
|
|
increased mitochondrial size |
J:63878
|
|
increased pancreatic beta cell mass |
J:63878,
J:92861
|
|
insulin resistance |
J:63878
|
|
pancreatic islet hyperplasia |
J:92861
|
|
postnatal growth retardation |
J:63878
|
|
small liver |
J:63878
|
Insrtm1Khn/Insrtm1Khn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
decreased body weight |
J:121640
|
|
decreased insulin secretion |
J:121640
|
|
normal
digestive/alimentary phenotype |
J:121640
|
|
hyperglycemia |
J:121640
|
|
impaired glucose tolerance |
J:121640
|
|
increased circulating insulin level |
J:121640
|
|
insulin resistance |
J:121640
|
|
polydipsia |
J:121640
|
|
polyuria |
J:121640
|
|
premature death |
J:121640
|
Irs1tm1Mfw/Irs1+
Irs2tm2Mfw/Irs2tm2Mfw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA * FVB/N
|
impaired glucose tolerance |
J:156999
|
Irs1tm1Mfw/Irs1tm1Mfw
Irs2tm2Mfw/Irs2tm2Mfw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
abnormal triglyceride level |
J:137845
|
|
decreased body size |
J:137845
|
|
decreased circulating cholesterol level |
J:137845
|
|
decreased circulating free fatty acids level |
J:137845
|
|
decreased circulating HDL cholesterol level |
J:137845
|
|
decreased circulating triglyceride level |
J:137845
|
|
decreased liver glycogen level |
J:137845
|
|
hyperglycemia |
J:137845
|
|
impaired glucose tolerance |
J:137845
|
|
increased circulating glucose level |
J:137845
|
|
increased circulating insulin level |
J:137845
|
|
increased susceptibility to autoimmune diabetes |
J:137845
|
|
insulin resistance |
J:137845
|
Irs1tm1Mfw/Irs1tm1Mfw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
impaired glucose tolerance |
J:137845
|
Irs1tm1Mfw/Irs1tm2.1Mfw
Irs2tm2Mfw/Irs2tm2Mfw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA * FVB/N
|
impaired glucose tolerance |
J:156999
|
|
increased circulating insulin level |
J:156999
|
|
insulin resistance |
J:156999
|
Irs1tm2.1Mfw/Irs1tm2.1Mfw
Irs2tm2Mfw/Irs2tm2Mfw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA * FVB/N
|
impaired glucose tolerance |
J:156999
|
|
increased circulating insulin level |
J:156999
|
Irs1tm2Tka/Irs1tm2Tka
Irs2tm2Tka/Irs2tm2Tka
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
increased susceptibility to autoimmune diabetes |
J:137846
|
|
insulin resistance |
J:137846
|
Irs1tm2Tka/Irs1tm2Tka
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
normal
homeostasis/metabolism phenotype |
J:137846
|
|
increased circulating insulin level |
J:137846
|
|
insulin resistance |
J:137846
|
Irs2tm2Mfw/Irs2tm2Mfw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
normal
homeostasis/metabolism phenotype |
J:137845
|
Irs2tm2Tka/Irs2tm2Tka
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
|
normal
homeostasis/metabolism phenotype |
J:137846
|
|
increased circulating insulin level |
J:137846
|
|
insulin resistance |
J:137846
|
Keap1tm1Mym/Keap1tm2Mym
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
decreased physiological sensitivity to xenobiotic |
J:103791
|
|
decreased susceptibility to xenobiotic induced morbidity/mortality |
J:103791
|
Klf14tm1.1Yec/Klf14tm1.1Yec
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
decreased circulating HDL cholesterol level |
J:226403
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
hemoperitoneum |
J:184949
|
|
increased cholangiocarcinoma incidence |
J:184949
|
|
increased hamartoma incidence |
J:184949
|
|
increased metastatic potential |
J:184949
|
|
premature death |
J:184949
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
hemoperitoneum |
J:184949
|
|
increased cholangiocarcinoma incidence |
J:184949
|
|
increased hamartoma incidence |
J:184949
|
|
increased metastatic potential |
J:184949
|
|
premature death |
J:184949
|
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
|
increased cholangiocarcinoma incidence |
J:184949
|
|
increased liver tumor incidence |
J:254370
|
Krastm4Tyj/Kras+
Ptentm2Mak/Pten+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
increased cholangiocarcinoma incidence |
J:254370
|
|
increased hepatocellular carcinoma incidence |
J:254370
|
|
increased liver tumor incidence |
J:254370
|
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
bile duct hyperplasia |
J:254370
|
|
distended abdomen |
J:254370
|
|
enlarged liver |
J:254370
|
|
hemorrhagic ascites |
J:254370
|
|
increased cholangiocarcinoma incidence |
J:254370
|
|
increased liver tumor incidence |
J:254370
|
|
jaundice |
J:254370
|
|
postnatal growth retardation |
J:254370
|
|
premature death |
J:254370
|
|
weight loss |
J:254370
|
Krastm4Tyj/Krastm4Tyj
Yap1tm1.1Dupa/Yap1tm1.1Dupa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
increased hepatocellular carcinoma incidence |
J:162628
|
Lamp2tm1Amcu/Y
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J
|
abnormal autophagy |
J:215605
|
|
abnormal enzyme/coenzyme activity |
J:215605
|
|
abnormal glucose homeostasis |
J:215605
|
|
abnormal lipid homeostasis |
J:215605
|
|
abnormal liver physiology |
J:215605
|
|
normal
cellular phenotype |
J:215605
|
|
decreased body weight |
J:215605
|
|
decreased brown fat cell lipid droplet size |
J:215605
|
|
decreased fasting circulating glucose level |
J:215605
|
|
decreased gonadal fat pad weight |
J:215605
|
|
decreased hepatic glucose production |
J:215605
|
|
decreased liver function |
J:215605
|
|
decreased liver glycogen level |
J:215605
|
|
decreased locomotor activity |
J:215605
|
|
decreased percent body fat/body weight |
J:215605
|
|
decreased white fat cell lipid droplet size |
J:215605
|
|
enhanced behavioral response to xenobiotic |
J:215605
|
|
enlarged liver |
J:215605
|
|
hepatic steatosis |
J:215605
|
|
improved glucose tolerance |
J:215605
|
|
increased carbon dioxide production |
J:215605
|
|
increased cellular glucose import |
J:215605
|
|
increased circulating alanine transaminase level |
J:215605
|
|
increased energy expenditure |
J:215605
|
|
increased hepatocyte apoptosis |
J:215605
|
|
increased liver triglyceride level |
J:215605
|
|
increased liver weight |
J:215605
|
|
increased oxygen consumption |
J:215605
|
|
increased respiratory quotient |
J:215605
|
|
increased susceptibility to weight gain |
J:215605
|
|
pale liver |
J:215605
|
|
weight loss |
J:215605
|
Ldlrtm1Her/Ldlrtm1Her
Nr1h3tm1.1Djm/Nr1h3tm1.1Djm
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6 * DBA
|
abnormal cholesterol homeostasis |
J:184536
|
|
decreased circulating cholesterol level |
J:184536
|
|
decreased circulating triglyceride level |
J:184536
|
|
decreased physiological sensitivity to xenobiotic |
J:184536
|
|
increased liver cholesterol level |
J:184536
|
|
increased susceptibility to atherosclerosis |
J:184536
|
Ldlrtm1Her/Ldlrtm1Her
Nr5a2tm1Sjns/Nr5a2tm1Sjns
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * C57BL/6J * DBA
|
abnormal feces composition |
J:215556
|
|
abnormal sterol level |
J:215556
|
|
normal
cardiovascular system phenotype |
J:215556
|
Lipatm1c(EUCOMM)Hmgu/Lipatm1c(EUCOMM)Hmgu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1Tg(Alb-cre)21Mgn
involves: C57BL/6J * C57BL/6N * C57BL/6NTac
|
abnormal carbohydrate metabolism |
J:270182
|
|
abnormal enzyme/coenzyme activity |
J:270182
|
|
abnormal hepatocyte morphology |
J:270182
|
|
abnormal lipid oxidation |
J:270182
|
|
abnormal tricarboxylic acid cycle |
J:270182
|
|
normal
adipose tissue phenotype |
J:270182
|
|
decreased gonadal fat pad weight |
J:270182
|
|
decreased liver triglyceride level |
J:270182
|
|
decreased susceptibility to diet-induced obesity |
J:270182
|
|
decreased triglyceride lipase activity |
J:270182
|
|
decreased unsaturated fatty acids level |
J:270182
|
|
enlarged liver |
J:270182
|
|
hepatic steatosis |
J:270182
|
|
impaired gluconeogenesis |
J:270182
|
|
improved glucose tolerance |
J:270182
|
|
increased circulating alanine transaminase level |
J:270182
|
|
increased circulating aspartate transaminase level |
J:270182
|
|
increased circulating cholesterol level |
J:270182
|
|
increased circulating ketone body level |
J:270182
|
|
increased circulating LDL cholesterol level |
J:270182
|
|
increased insulin sensitivity |
J:270182
|
|
increased liver cholesterol level |
J:270182
|
|
increased liver weight |
J:270182
|
|
increased respiratory quotient |
J:270182
|
|
increased unsaturated fatty acids level |
J:270182
|
|
liver fibrosis |
J:270182
|
|
liver inflammation |
J:270182
|
|
pale liver |
J:270182
|
Lman1tm1c(KOMP)Wtsi/Lman1tm1c(KOMP)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6J * C57BL/6N
|
abnormal blood homeostasis |
J:213133
|
Lpcat3tm1c(EUCOMM)Wtsi/Lpcat3tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * SJL
|
abnormal circulating apolipoprotein level |
J:220827
|
|
abnormal lipid homeostasis |
J:220827
|
|
abnormal lipid level |
J:220827
|
|
abnormal phospholipid level |
J:220827
|
|
decreased circulating triglyceride level |
J:220827
|
|
decreased circulating VLDL phospholipid level |
J:220827
|
|
decreased circulating VLDL triglyceride level |
J:220827
|
|
hepatic steatosis |
J:220827
|
|
increased liver cholesterol level |
J:220827
|
|
increased liver triglyceride level |
J:220827
|
Mad2l1bptm1.1Itl/Mad2l1bptm1.1Itl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * C57BL/6NTac
|
abnormal endocytosis |
J:234643
|
|
abnormal enzyme/coenzyme activity |
J:234643
|
|
abnormal hepatocyte physiology |
J:234643
|
|
abnormal liver physiology |
J:234643
|
|
aneuploidy |
J:234643
|
|
decreased liver glycogen level |
J:234643
|
|
decreased liver triglyceride level |
J:234643
|
|
hyperglycemia |
J:234643
|
|
impaired glucose tolerance |
J:234643
|
|
increased circulating insulin level |
J:234643
|
|
increased circulating triglyceride level |
J:234643
|
|
insulin resistance |
J:234643
|
|
normal
mortality/aging |
J:234643
|
Map3k7tm1Aki/Map3k7tm1Aki
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal bile duct morphology |
J:160521
|
|
abnormal hepatocyte morphology |
J:160521
|
|
focal hepatic necrosis |
J:160521
|
|
increased circulating bilirubin level |
J:160521
|
|
increased hepatocyte proliferation |
J:160521
|
Mcutm1.1Jmol/Mcutm1.1Jmol
Speer6-ps1Tg(Alb-cre)21Mgn/0
involves: 129S6/SvEvTac * C57BL/6 * DBA
|
normal
cellular phenotype |
J:298361
|
|
normal
liver/biliary system phenotype |
J:298361
|
Mettm1Sst/Mettm1Sst
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal hepatocyte physiology |
J:89236
|
|
abnormal response to injury |
J:89236
|
|
abnormal susceptibility to injury induced morbidity/mortality |
J:89236
|
|
impaired liver regeneration |
J:89236
|
|
impaired wound healing |
J:89236
|
|
increased hepatocyte apoptosis |
J:89236
|
|
liver failure |
J:89236
|
|
liver hemorrhage |
J:89236
|
Mia2tm1Zhxu/Mia2tm1Zhxu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:268333
|
|
abnormal liver morphology |
J:268333
|
|
abnormal liver physiology |
J:268333
|
|
decreased body size |
J:268333
|
|
decreased circulating cholesterol level |
J:268333
|
|
decreased circulating triglyceride level |
J:268333
|
|
enlarged liver |
J:268333
|
|
hepatic steatosis |
J:268333
|
|
increased liver cholesterol level |
J:268333
|
|
increased liver triglyceride level |
J:268333
|
|
pale liver |
J:268333
|
Mir100em1Nju/Mir100em1Nju
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
increased circulating alanine transaminase level |
J:281439
|
|
increased circulating aspartate transaminase level |
J:281439
|
|
increased hepatocyte karyomegaly |
J:281439
|
|
liver inflammation |
J:281439
|
Mir122tm1.2Kgh/Mir122+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
increased hepatocellular carcinoma incidence |
J:190067
|
Mir122tm1.2Kgh/Mir122tm1.2Kgh
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
abnormal circulating enzyme level |
J:190067
|
|
abnormal lipid homeostasis |
J:190067
|
|
abnormal liver physiology |
J:190067
|
|
abnormal oval cell physiology |
J:190067
|
|
bile duct proliferation |
J:190067
|
|
decreased circulating cholesterol level |
J:190067
|
|
decreased circulating HDL cholesterol level |
J:190067
|
|
decreased circulating LDL cholesterol level |
J:190067
|
|
decreased liver glycogen level |
J:190067
|
|
increased bile salt level |
J:190067
|
|
increased circulating alanine transaminase level |
J:190067
|
|
increased circulating alkaline phosphatase level |
J:190067
|
|
increased circulating interleukin-6 level |
J:190067
|
|
increased hepatocellular carcinoma incidence |
J:190067
|
|
increased interleukin-6 secretion |
J:190067
|
|
increased liver triglyceride level |
J:190067
|
|
increased liver tumor incidence |
J:190067
|
|
increased monocyte cell number |
J:190067
|
|
increased neutrophil cell number |
J:190067
|
|
increased tumor necrosis factor secretion |
J:190067
|
|
liver fibrosis |
J:190067
|
|
liver inflammation |
J:190067
|
|
microvesicular hepatic steatosis |
J:190067
|
Mirc53tm1.1Gning/Mirc53tm1.1Gning
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
decreased susceptibility to injury |
J:278082
|
Mob1atm1.1Asuz/Mob1atm1.1Asuz
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Mob1bGt(CC0690)Wtsi Mob1atm1.1Asuz Speer6-ps1Tg(Alb-cre)21Mgn
|
abdomen swellings |
J:228499
|
|
abnormal bile duct physiology |
J:228499
|
|
abnormal cholangiocyte morphology |
J:228499
|
|
enlarged liver |
J:228499
|
|
increased cholangiocarcinoma incidence |
J:228499
|
|
increased circulating bilirubin level |
J:228499
|
|
increased hepatobiliary system tumor incidence |
J:228499
|
|
increased hepatocellular carcinoma incidence |
J:228499
|
|
increased hepatocyte number |
J:228499
|
|
increased hepatocyte proliferation |
J:228499
|
|
increased liver adenoma incidence |
J:228499
|
|
jaundice |
J:228499
|
|
liver fibrosis |
J:228499
|
|
normal
liver/biliary system phenotype |
J:228499
|
|
postnatal lethality, incomplete penetrance |
J:228499
|
|
premature death |
J:228499
|
Mob1atm1.1Asuz/Mob1atm1.1Asuz
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tgfbr2tm1Roes/Tgfbr2tm1Roes
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal cholangiocyte morphology |
J:228499
|
|
increased liver weight |
J:228499
|
|
liver fibrosis |
J:228499
|
Mob1atm1.1Asuz/Mob1atm1.1Asuz
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
Wwtr1tm1Hku/Wwtr1tm1Hku
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal cholangiocyte morphology |
J:228499
|
|
increased liver weight |
J:228499
|
|
liver fibrosis |
J:228499
|
Mob1atm1.1Asuz/Mob1atm1.1Asuz
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
Yap1tm1c(KOMP)Mbp/Yap1tm1c(KOMP)Mbp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * DBA
|
abnormal cholangiocyte morphology |
J:228499
|
|
increased liver weight |
J:228499
|
|
liver fibrosis |
J:228499
|
Mpc1tm1c(EUCOMM)Wtsi/Mpc1tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA
|
abnormal gluconeogenesis |
J:236662
|
|
abnormal mitochondrial physiology |
J:236662
|
|
normal
behavior/neurological phenotype |
J:236662
|
|
decreased body weight |
J:236662
|
|
decreased circulating cholesterol level |
J:236662
|
|
decreased circulating glucose level |
J:236662
|
|
decreased circulating triglyceride level |
J:236662
|
|
decreased respiratory quotient |
J:236662
|
|
normal
homeostasis/metabolism phenotype |
J:236662
|
|
improved glucose tolerance |
J:236662
|
|
increased circulating ketone body level |
J:236662
|
|
increased circulating lactate level |
J:236662
|
|
increased fatty acid oxidation |
J:236662
|
|
increased triglyceride level |
J:236662
|
Mtch2tm2Atgr/Mtch2tm2.1Atgr
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
liver failure |
J:209127
|
Naa40tm1Qwzh/Naa40tm1Qwzh
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn Naa40tm1Qwzh
|
abnormal eating behavior |
J:183119
|
|
abnormal lipid homeostasis |
J:183119
|
|
decreased circulating LDL cholesterol level |
J:183119
|
|
decreased circulating VLDL triglyceride level |
J:183119
|
|
decreased liver free fatty acids level |
J:183119
|
|
decreased liver triglyceride level |
J:183119
|
|
decreased percent body fat/body weight |
J:183119
|
|
decreased respiratory quotient |
J:183119
|
|
decreased susceptibility to age-related hepatic steatosis |
J:183119
|
|
decreased total body fat amount |
J:183119
|
|
improved glucose tolerance |
J:183119
|
|
increased body weight |
J:183119
|
|
increased circulating glucose level |
J:183119
|
|
increased energy expenditure |
J:183119
|
|
increased fatty acid oxidation |
J:183119
|
|
increased lean body mass |
J:183119
|
|
increased oxygen consumption |
J:183119
|
Ncor1tm1Anh/Ncor1tm1Anh
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * DBA
|
decreased circulating LDL cholesterol level |
J:142045
|
|
decreased circulating thyroxine level |
J:142045
|
Ndst1tm1Je/Ndst1tm1Je
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
abnormal hepatocyte physiology |
J:158299
|
Nf2tm2Gth/Nf2tm2Gth
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal liver morphology |
J:162628
|
|
bile duct hyperplasia |
J:162628
|
|
bile duct proliferation |
J:162628
|
|
enlarged liver |
J:162628
|
|
increased hepatobiliary system tumor incidence |
J:162628
|
|
increased hepatocellular carcinoma incidence |
J:162628
|
Nf2tm2Gth/Nf2tm2Gth
Yap1tm1.1Dupa/Yap1+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
enlarged liver |
J:162628
|
|
normal
liver/biliary system phenotype |
J:162628
|
|
normal
neoplasm |
J:162628
|
Nf2tm2Gth/Nf2tm2Gth
Yap1tm1.1Dupa/Yap1tm1.1Dupa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
normal
liver/biliary system phenotype |
J:162628
|
|
normal
neoplasm |
J:162628
|
Nfe2l1tm1Jefc/Nfe2l1tm1Ywk
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129X1/SvJ * C57BL/6J
|
hepatic necrosis |
J:97188
|
|
hepatic steatosis |
J:97188
|
|
increased circulating alanine transaminase level |
J:97188
|
|
increased hepatocellular carcinoma incidence |
J:97188
|
|
increased liver adenoma incidence |
J:97188
|
|
liver fibrosis |
J:97188
|
|
liver inflammation |
J:97188
|
Nfe2l1tm1Mym/Nfe2l1tm1Mym
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
hepatic steatosis |
J:143468
|
|
increased circulating alanine transaminase level |
J:143468
|
|
increased circulating aspartate transaminase level |
J:143468
|
Notch2tm2Grid/Notch2tm3Grid
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * C57BL/6 * DBA
|
abnormal bile duct morphology |
J:133171
|
|
decreased body size |
J:133171
|
|
decreased body weight |
J:133171
|
|
focal hepatic necrosis |
J:133171
|
|
normal
homeostasis/metabolism phenotype |
J:133171
|
|
increased circulating alanine transaminase level |
J:133171
|
|
increased circulating alkaline phosphatase level |
J:133171
|
|
increased circulating bilirubin level |
J:133171
|
Notch2tm3Grid/Notch2tm3.1Grid
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * C57BL/6 * DBA
|
abnormal bile duct morphology |
J:133171
|
|
decreased body size |
J:133171
|
|
decreased body weight |
J:133171
|
|
focal hepatic necrosis |
J:133171
|
|
normal
homeostasis/metabolism phenotype |
J:133171
|
|
increased circulating alanine transaminase level |
J:133171
|
|
increased circulating alkaline phosphatase level |
J:133171
|
|
increased circulating bilirubin level |
J:133171
|
Nr0b2tm1Mjev/Nr0b2tm1Mjev
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEvBrd * C57BL/6 * DBA
|
decreased circulating cholesterol level |
J:149005
|
|
decreased circulating LDL cholesterol level |
J:149005
|
Nr1h3tm1.1Djm/Nr1h3tm1.1Djm
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEv * C57BL/6 * DBA
|
abnormal lipid homeostasis |
J:184536
|
|
decreased physiological sensitivity to xenobiotic |
J:184536
|
|
increased liver cholesterol level |
J:184536
|
|
increased liver weight |
J:184536
|
Nr1h3tm1Djm/Nr1h3tm1Djm
Nus1tm1.1Qrm/Nus1tm1.1Qrm
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6 * DBA * SJL
|
normal
homeostasis/metabolism phenotype |
J:243753
|
|
increased liver cholesterol level |
J:243753
|
Nr5a2tm1Sakl/Nr5a2tm1Sakl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * DBA
|
abnormal bile composition |
J:135822
|
|
decreased circulating aspartate transaminase level |
J:135822
|
|
decreased circulating cholesterol level |
J:135822
|
Nus1tm1.1Qrm/Nus1tm1.1Qrm
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6 * DBA * SJL
|
abnormal circulating cholesterol level |
J:243753
|
|
abnormal lipid homeostasis |
J:243753
|
|
decreased liver cholesterol level |
J:243753
|
|
increased circulating free fatty acids level |
J:243753
|
|
increased circulating triglyceride level |
J:243753
|
|
increased liver free fatty acids level |
J:243753
|
|
increased liver triglyceride level |
J:243753
|
Orc1tm1.1Gle/Orc1tm1.1Gle
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA * SJL
|
abnormal DNA replication |
J:272584
|
|
decreased hepatocyte number |
J:272584
|
|
increased hepatocyte karyomegaly |
J:272584
|
|
increased hepatocyte proliferation |
J:272584
|
|
normal
liver/biliary system phenotype |
J:272584
|
|
polyploidy |
J:272584
|
Orc1tm1.1Gle/Orc1tm1.2Gle
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA * SJL
|
abnormal DNA replication |
J:272584
|
|
decreased hepatocyte number |
J:272584
|
|
increased hepatocyte karyomegaly |
J:272584
|
|
polyploidy |
J:272584
|
Pck1tm1.1Mgn/Pck1tm1.1Mgn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac
|
decreased liver glycogen level |
J:63929
|
|
enlarged liver |
J:63929
|
|
increased circulating free fatty acids level |
J:63929
|
|
increased circulating triglyceride level |
J:63929
|
|
increased liver triglyceride level |
J:63929
|
|
increased liver weight |
J:63929
|
|
pale liver |
J:63929
|
Pcsk9tm1.1Prat/Pcsk9tm1.1Prat
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
decreased circulating cholesterol level |
J:169834
|
|
decreased circulating HDL cholesterol level |
J:169834
|
|
decreased circulating LDL cholesterol level |
J:169834
|
Pcxtm1c(EUCOMM)Wtsi/Pcxtm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * DBA * SJL
|
abnormal amino acid metabolism |
J:332296
|
|
abnormal fatty acid oxidation |
J:332296
|
|
abnormal insulin clearance |
J:332296
|
|
abnormal insulin secretion |
J:332296
|
|
abnormal liver physiology |
J:332296
|
|
abnormal mitochondrial physiology |
J:332296
|
|
decreased circulating glucose level |
J:332296
|
|
decreased fasting circulating glucose level |
J:332296
|
|
normal
growth/size/body region phenotype |
J:332296
|
|
hepatic steatosis |
J:332296
|
|
hypoglycemia |
J:332296
|
|
impaired gluconeogenesis |
J:332296
|
|
improved glucose tolerance |
J:332296
|
|
increased circulating free fatty acids level |
J:332296
|
|
increased circulating ketone body level |
J:332296
|
|
increased circulating lactate level |
J:332296
|
|
increased circulating triglyceride level |
J:332296
|
|
increased kidney weight |
J:332296
|
|
increased liver triglyceride level |
J:332296
|
|
increased susceptibility to weight loss |
J:332296
|
Pcyt2tm1.1Suja/Pcyt2tm1.1Suja
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
decreased circulating triglyceride level |
J:155630
|
|
hepatic steatosis |
J:155630
|
|
increased liver cholesterol level |
J:155630
|
|
increased liver triglyceride level |
J:155630
|
|
pale liver |
J:155630
|
Pdss2tm1Dalg/Pdss2tm1Dalg
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal aerobic respiration |
J:136670
|
|
abnormal circulating cholesterol level |
J:136670
|
|
abnormal energy homeostasis |
J:136670
|
|
abnormal mitophagy |
J:136670
|
|
abnormal respiratory electron transport chain |
J:136670
|
Pex5tm1Pec/Pex5tm1Pec
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
abnormal bile salt homeostasis |
J:121804
|
|
abnormal blood homeostasis |
J:112503
|
|
abnormal cell morphology |
J:112503
|
|
abnormal endoplasmic reticulum morphology |
J:112503
|
|
abnormal fatty acid beta-oxidation |
J:121804
|
|
abnormal glucose homeostasis |
J:112503
|
|
abnormal liver morphology |
J:112503
|
|
abnormal lysosome morphology |
J:112503
|
|
abnormal mitochondrial ATP synthesis coupled electron transport |
J:112503
|
|
abnormal mitochondrial crista morphology |
J:112503
|
|
abnormal mitochondrial inner membrane morphology |
J:112503
|
|
abnormal mitochondrial shape |
J:112503
|
|
abnormal postnatal growth |
J:112503
|
|
abnormal respiratory electron transport chain |
J:112503
|
|
decreased body weight |
J:112503
|
|
enlarged liver |
J:112503
|
|
increased circulating lactate level |
J:112503
|
|
increased liver tumor incidence |
J:112503
|
|
liver hyperplasia |
J:112503
|
|
normal
liver/biliary system phenotype |
J:112503
|
|
slow postnatal weight gain |
J:112503
|
Pik3c3tm1c(EUCOMM)Wtsi/Pik3c3tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * DBA
|
abnormal liver morphology |
J:182628
|
|
decreased body size |
J:182628
|
|
decreased liver glycogen level |
J:182628
|
|
enlarged liver |
J:182628
|
|
hepatic steatosis |
J:182628
|
|
pale liver |
J:182628
|
|
premature death |
J:182628
|
Pik3c3tm1c(EUCOMM)Wtsi/Pik3c3tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(CAG-EGFP/Map1lc3b)53Nmz/0
involves: C57BL/6 * C57BL/6N * C57BL/6NCrj * DBA
|
abnormal autophagy |
J:182628
|
|
abnormal liver physiology |
J:182628
|
Pnpla2tm1Gam/Pnpla2tm1Gam
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA
|
abnormal cholangiocyte morphology |
J:185116
|
|
abnormal hepatocyte morphology |
J:185116
|
|
decreased basal metabolism |
J:185116
|
|
decreased fatty acid oxidation |
J:185116
|
|
increased circulating alanine transaminase level |
J:185116
|
|
increased circulating free fatty acids level |
J:185116
|
|
increased liver triglyceride level |
J:185116
|
|
increased liver weight |
J:185116
|
|
macrovesicular hepatic steatosis |
J:185116
|
|
microvesicular hepatic steatosis |
J:185116
|
Pnpt1tm1Teit/Pnpt1tm1Teit
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal mitochondrial ATP synthesis coupled electron transport |
J:167932
|
|
abnormal mitochondrial crista morphology |
J:167932
|
|
abnormal mitochondrial physiology |
J:167932
|
Polr2mtm1.1Rgr/Polr2mtm1.1Rgr
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal hepatocyte physiology |
J:291184
|
|
decreased circulating triglyceride level |
J:291184
|
|
increased circulating alkaline phosphatase level |
J:291184
|
|
increased hepatocyte karyomegaly |
J:291184
|
|
normal
liver/biliary system phenotype |
J:291184
|
Polr2mtm1.1Rgr/Polr2mtm1.1Rgr
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:291184
|
|
abnormal liver morphology |
J:291184
|
|
increased hepatocyte apoptosis |
J:291184
|
|
increased hepatocyte proliferation |
J:291184
|
Portm1Ding/Por+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * C57BL/6 * DBA
|
abnormal enzyme/coenzyme activity |
J:84422
|
Portm1Ding/Portm1Ding
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * C57BL/6 * DBA
|
abnormal enzyme/coenzyme activity |
J:84422
|
|
abnormal liver morphology |
J:84422
|
|
decreased circulating cholesterol level |
J:84422
|
|
enhanced behavioral response to xenobiotic |
J:84422
|
|
hepatic necrosis |
J:84422
|
|
hepatic steatosis |
J:84422
|
|
increased liver weight |
J:84422
|
|
pale liver |
J:84422
|
Portm1Wolf/Portm1Wolf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal acetaminophen metabolism |
J:82951
|
|
abnormal bile salt level |
J:82951
|
|
abnormal xenobiotic pharmacokinetics |
J:82951
|
|
decreased circulating cholesterol level |
J:82951
|
|
decreased circulating triglyceride level |
J:82951
|
|
decreased litter size |
J:82951
|
|
enlarged liver |
J:82951
|
|
increased circulating alanine transaminase level |
J:82951
|
|
macrovesicular hepatic steatosis |
J:82951
|
|
microvesicular hepatic steatosis |
J:82951
|
|
pale liver |
J:82951
|
|
reduced fertility |
J:82951
|
Portm2Wolf/Portm1Wolf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal acetaminophen metabolism |
J:82951
|
|
abnormal bile salt level |
J:82951
|
|
abnormal xenobiotic pharmacokinetics |
J:82951
|
|
decreased circulating cholesterol level |
J:82951
|
|
decreased circulating triglyceride level |
J:82951
|
|
decreased litter size |
J:82951
|
|
enlarged liver |
J:82951
|
|
increased circulating alanine transaminase level |
J:82951
|
|
macrovesicular hepatic steatosis |
J:82951
|
|
microvesicular hepatic steatosis |
J:82951
|
|
pale liver |
J:82951
|
|
reduced fertility |
J:82951
|
Portm3Ding/Portm3Ding
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal enzyme/coenzyme activity |
J:159168
|
|
normal
behavior/neurological phenotype |
J:159168
|
|
female infertility |
J:159168
|
|
normal
growth/size/body region phenotype |
J:159168
|
|
normal
homeostasis/metabolism phenotype |
J:159168
|
|
increased circulating progesterone level |
J:159168
|
|
increased circulating testosterone level |
J:159168
|
|
normal
mortality/aging |
J:159168
|
Ppargc1atm2Brsp/Ppargc1atm2Brsp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6 * DBA
|
abnormal blood homeostasis |
J:115197
|
|
abnormal cell physiology |
J:115197
|
Ppdpftm1Nju/Ppdpftm1Nju
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
hepatic steatosis |
J:307283
|
|
impaired glucose tolerance |
J:307283
|
|
increased body weight |
J:307283
|
|
increased circulating free fatty acids level |
J:307283
|
|
increased circulating triglyceride level |
J:307283
|
|
increased lipogenesis |
J:307283
|
|
increased liver triglyceride level |
J:307283
|
|
increased liver weight |
J:307283
|
|
increased susceptibility to diet-induced hepatic steatosis |
J:307283
|
|
insulin resistance |
J:307283
|
Prkacatm3Gsm/Prkacatm3Gsm
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129X1/SvJ * C57BL/6J
|
abnormal glucose homeostasis |
J:103418
|
|
abnormal glycogen homeostasis |
J:103418
|
|
normal
adipose tissue phenotype |
J:103418
|
|
decreased body length |
J:103418
|
|
decreased body size |
J:103418
|
|
decreased circulating insulin level |
J:103418
|
|
decreased insulin secretion |
J:103418
|
|
decreased liver glycogen level |
J:103418
|
|
impaired glucose tolerance |
J:103418
|
|
increased circulating glucose level |
J:103418
|
|
increased circulating triglyceride level |
J:103418
|
Pros1tm1Grl/Pros1tm1Grl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/SvImJ * C57BL/6 * DBA
|
abnormal thrombosis |
J:198769
|
|
normal
cardiovascular system phenotype |
J:198769
|
|
normal
mortality/aging |
J:198769
|
Psmd4tm2Smta/Psmd4tm2Smta
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: C57BL/6 * CBA * DBA
|
abnormal liver physiology |
J:126546
|
Psmg1tm1.1Smta/Psmg1tm1.1Smta
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * CBA * DBA
|
abnormal hepatic cord morphology |
J:162790
|
|
abnormal hepatocyte morphology |
J:162790
|
|
abnormal hepatocyte physiology |
J:162790
|
|
abnormal liver sinusoid morphology |
J:162790
|
|
normal
mortality/aging |
J:162790
|
Ptentm1Hwu/Ptentm1Hwu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
|
abnormal fatty acids level |
J:88441
|
|
abnormal liver morphology |
J:218587
|
|
decreased circulating free fatty acids level |
J:88441
|
|
decreased circulating glucose level |
J:88441
|
|
decreased circulating insulin level |
J:88441
|
|
decreased circulating leptin level |
J:88441
|
|
decreased total body fat amount |
J:88441
|
|
enlarged liver |
J:88441,
J:171445
|
|
hepatic steatosis |
J:88441,
J:160759,
J:218587
|
|
impaired lipolysis |
J:88441
|
|
improved glucose tolerance |
J:88441
|
|
increased cholangiocarcinoma incidence |
J:218587
|
|
increased circulating alanine transaminase level |
J:218587
|
|
increased hepatocellular carcinoma incidence |
J:218587
|
|
increased hepatocyte apoptosis |
J:218587
|
|
increased hepatocyte proliferation |
J:218587
|
|
increased insulin sensitivity |
J:88441
|
|
increased liver glycogen level |
J:88441
|
|
increased liver triglyceride level |
J:88441,
J:160759
|
|
increased liver tumor incidence |
J:218587
|
|
increased liver weight |
J:88441,
J:160759
|
|
macrovesicular hepatic steatosis |
J:171445
|
|
oxidative stress |
J:218587
|
|
pale liver |
J:88441
|
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * DBA
|
abnormal cellular cholesterol metabolism |
J:90905
|
|
abnormal hepatocyte morphology |
J:90905
|
|
abnormal liver sinusoid morphology |
J:90905
|
|
decreased circulating insulin level |
J:90905
|
|
decreased fasting circulating glucose level |
J:90905
|
|
enlarged liver |
J:90905
|
|
increased circulating alanine transaminase level |
J:90905
|
|
increased circulating alkaline phosphatase level |
J:90905
|
|
increased circulating aspartate transaminase level |
J:90905
|
|
increased hepatocellular carcinoma incidence |
J:90905
|
|
increased hepatocyte number |
J:90905
|
|
increased hepatocyte proliferation |
J:90905
|
|
increased insulin sensitivity |
J:90905
|
|
increased liver adenoma incidence |
J:90905
|
|
increased liver triglyceride level |
J:90905
|
|
increased liver weight |
J:90905
|
|
increased metastatic potential |
J:90905
|
|
increased saturated fatty acids level |
J:90905
|
|
Mallory bodies |
J:90905
|
|
microvesicular hepatic steatosis |
J:90905
|
|
oxidative stress |
J:90905
|
|
pale liver |
J:90905
|
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:138099
|
|
abnormal hepatocyte physiology |
J:220381
|
|
abnormal liver morphology |
J:138099
|
|
enlarged liver |
J:138099
|
|
hepatic steatosis |
J:138099
|
|
increased circulating alanine transaminase level |
J:138099
|
|
increased circulating alkaline phosphatase level |
J:138099
|
|
increased hepatocellular carcinoma incidence |
J:138099
|
|
increased hepatocyte proliferation |
J:138099
|
|
increased liver adenoma incidence |
J:138099
|
|
increased liver cholesterol level |
J:138099
|
|
increased liver triglyceride level |
J:138099
|
|
liver fibrosis |
J:138099
|
|
liver inflammation |
J:138099
|
|
Mallory bodies |
J:138099
|
|
pale liver |
J:138099
|
Ptpn1tm2Bbk/Ptpn1tm2Bbk
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
normal
growth/size/body region phenotype |
J:111969
|
Ptpn11tm1Gsf/Ptpn11tm1Gsf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:172422
|
|
abnormal liver morphology |
J:172422
|
|
abnormal liver parenchyma morphology |
J:172422
|
|
focal hepatic necrosis |
J:172422
|
|
hepatic necrosis |
J:172422
|
|
increased acute inflammation |
J:172422
|
|
increased circulating alanine transaminase level |
J:172422
|
|
increased circulating aspartate transaminase level |
J:172422
|
|
increased circulating interleukin-6 level |
J:172422
|
|
increased hepatocyte proliferation |
J:172422
|
|
increased incidence of tumors by chemical induction |
J:172422
|
|
increased liver adenoma incidence |
J:172422
|
|
liver fibrosis |
J:172422
|
|
liver hyperplasia |
J:172422
|
|
liver inflammation |
J:172422
|
|
weight loss |
J:172422
|
Ptpn11tm1Gsf/Ptpn11tm1Gsf
Stat3tm1Vpo/Stat3tm1Vpo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
|
increased circulating alanine transaminase level |
J:172422
|
|
increased incidence of tumors by chemical induction |
J:172422
|
|
liver inflammation |
J:172422
|
Ptpn11tm3Bgn/Ptpn11tm3Bgn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129X1/SvJ * C57BL/6 * C57BL/6J * DBA
|
decreased circulating glucose level |
J:167406
|
|
decreased circulating insulin level |
J:167406
|
|
decreased circulating triglyceride level |
J:167406
|
|
improved glucose tolerance |
J:167406
|
|
increased insulin sensitivity |
J:167406
|
Raratm3Ipc/Rara+
Speer6-ps1Tg(Alb-cre)21Mgn/?
Trim24tm1Los/Trim24tm1Los
involves: 129/Sv * C57BL/6 * DBA * SJL
|
increased hepatocyte proliferation |
J:130210
|
Raratm3Ipc/Raratm3Ipc
Speer6-ps1Tg(Alb-cre)21Mgn/?
Trim24tm1Los/Trim24tm1Los
involves: 129/Sv * C57BL/6 * DBA * SJL
|
increased hepatocyte proliferation |
J:130210
|
Rptortm1.1Dmsa/Rptortm1.1Dmsa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEv * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:167208
|
|
abnormal liver physiology |
J:167208
|
|
increased circulating ketone body level |
J:167208
|
|
small liver |
J:167208
|
Rr27tm2Msb/Rr27+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
paternal imprinting |
J:105567
|
Rragatm2Dmsa/Rragatm2Dmsa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
|
decreased circulating glucose level |
J:213516
|
|
increased insulin sensitivity |
J:213516
|
Rubcnlem1Qsun/Rubcnlem1Qsun
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn Rubcnlem1Qsun
|
abnormal liver physiology |
J:272052
|
|
decreased circulating ketone body level |
J:272052
|
|
hepatic steatosis |
J:272052
|
|
impaired autophagy |
J:272052
|
|
increased liver glycogen level |
J:272052
|
|
increased liver triglyceride level |
J:272052
|
|
increased liver weight |
J:272052
|
|
liver fibrosis |
J:272052
|
Sav1tm1.1Rjo/Sav1tm1.1Rjo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL
|
increased carcinoma incidence |
J:156531
|
|
increased hepatocellular carcinoma incidence |
J:156531
|
|
increased hepatocyte proliferation |
J:156531
|
|
increased liver weight |
J:156531
|
Sav1tm2.1Dlim/Sav1tm2.1Dlim
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:160325
|
|
abnormal liver morphology |
J:160325
|
|
abnormal oval cell morphology |
J:160325
|
|
abnormal oval cell physiology |
J:160325
|
|
abnormal portal lobule morphology |
J:160325
|
|
enlarged liver |
J:160325
|
|
increased hepatocellular carcinoma incidence |
J:238319
|
|
increased hepatoma incidence |
J:160325
|
|
increased liver weight |
J:160325
|
|
normal
liver/biliary system phenotype |
J:160325
|
Scarb1tm1Thh/Scarb1tm1Thh
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Scarb1tm1Thh Speer6-ps1Tg(Alb-cre)21Mgn
|
increased circulating cholesterol level |
J:114663
|
|
increased circulating HDL cholesterol level |
J:114663
|
|
increased circulating interleukin-6 level |
J:114663
|
|
increased susceptibility to atherosclerosis |
J:114663
|
Scd1tm2Ntam/Scd1tm2Ntam
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn Scd1tm2Ntam
|
abnormal fat pad morphology |
J:130441
|
|
abnormal gluconeogenesis |
J:130441
|
|
abnormal lipid homeostasis |
J:130441
|
|
abnormal liver physiology |
J:130441
|
|
normal
behavior/neurological phenotype |
J:130441
|
|
decreased circulating glucose level |
J:130441
|
|
decreased circulating triglyceride level |
J:130441
|
|
decreased circulating VLDL triglyceride level |
J:130441
|
|
decreased gonadal fat pad weight |
J:130441
|
|
decreased inguinal fat pad weight |
J:130441
|
|
decreased liver glycogen level |
J:130441
|
|
decreased liver triglyceride level |
J:130441
|
|
decreased retroperitoneal fat pad weight |
J:130441
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:130441
|
|
decreased susceptibility to diet-induced obesity |
J:130441
|
|
decreased white adipose tissue amount |
J:130441
|
|
normal
homeostasis/metabolism phenotype |
J:130441
|
|
increased circulating cholesterol level |
J:130441
|
Sco1tm1c(KOMP)Wtsi/Sco1tm1c(KOMP)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * DBA
|
abnormal liver morphology |
J:222036
|
|
abnormal mitochondrial physiology |
J:222036
|
|
decreased body size |
J:222036
|
|
decreased kidney copper level |
J:222036
|
|
decreased leukocyte cell number |
J:222036
|
|
decreased liver copper level |
J:222036
|
|
decreased spleen white pulp amount |
J:222036
|
|
normal
hematopoietic system phenotype |
J:222036
|
|
hepatic steatosis |
J:222036
|
|
increased liver cholesterol level |
J:222036
|
|
increased liver iron level |
J:222036
|
|
increased liver triglyceride level |
J:222036
|
|
increased mitochondrial number |
J:222036
|
|
increased spleen iron level |
J:222036
|
|
premature death |
J:222036
|
|
spleen atrophy |
J:222036
|
|
weight loss |
J:222036
|
Sec24ctm1c(EUCOMM)Wtsi/Sec24ctm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA * SJL
|
normal
growth/size/body region phenotype |
J:232065
|
|
normal
homeostasis/metabolism phenotype |
J:232065
|
Secisbp2tm1c(EUCOMM)Wtsi/Secisbp2tm1c(EUCOMM)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * DBA
|
normal
liver/biliary system phenotype |
J:213080
|
Selenoptm3.1Rfb/Selenoptm3.1Rfb
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal gait |
J:192636
|
|
abnormal selenium level |
J:192636
|
|
decreased body weight |
J:192636
|
|
increased urine selenium level |
J:192636
|
|
limb grasping |
J:192636
|
|
oligozoospermia |
J:192636
|
|
teratozoospermia |
J:192636
|
Sephs1tm1.1Dhat/Sephs1tm1.1Dhat
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6J
|
abnormal enzyme/coenzyme activity |
J:245139
|
|
decreased liver iron level |
J:245139
|
|
decreased liver manganese level |
J:245139
|
Sirt3tm1.1Auw/Sirt3tm1.1Auw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6J * DBA
|
normal
homeostasis/metabolism phenotype |
J:207274
|
Slc25a4tm2Dwa/Slc25a4tm2Dwa
Slc25a5tm1Dwa/Y
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: 129S4/SvJae
|
abnormal aerobic respiration |
J:88165
|
Slc25a28tm1.1Dwrd/Slc25a28tm1.1Dwrd
Slc25a37tm1.1Kapl/Slc25a37tm1.1Kapl
Speer6-ps1Tg(Alb-cre)21Mgn/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * DBA
|
decreased liver iron level |
J:300667
|
Slc25a28tm1.1Dwrd/Slc25a28tm1.1Dwrd
Speer6-ps1Tg(Alb-cre)21Mgn/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * DBA
|
abnormal oxidative phosphorylation |
J:300667
|
|
decreased liver iron level |
J:300667
|
|
normal
embryo phenotype |
J:300667
|
Slc25a28tm1.2Dwrd/Slc25a28tm1.2Dwrd
Slc25a37tm1.1Kapl/Slc25a37tm1.1Kapl
Speer6-ps1Tg(Alb-cre)21Mgn/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * DBA
|
abnormal oxidative phosphorylation |
J:300667
|
|
normal
embryo phenotype |
J:300667
|
|
impaired liver regeneration |
J:300667
|
Slc25a37tm1.1Kapl/Slc25a37tm1.1Kapl
Speer6-ps1Tg(Alb-cre)21Mgn/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * DBA
|
abnormal oxidative phosphorylation |
J:300667
|
|
decreased liver iron level |
J:300667
|
|
impaired liver regeneration |
J:300667
|
Slc25a37tm1.1Kapl/Slc25a37tm1.2Kapl
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr * DBA
|
abnormal iron homeostasis |
J:173284
|
|
cholestasis |
J:173284
|
|
enlarged liver |
J:173284
|
|
enlarged spleen |
J:173284
|
|
normal
homeostasis/metabolism phenotype |
J:173284
|
|
liver fibrosis |
J:173284
|
|
normal
mortality/aging |
J:173284
|
Smad2tm1.1Epb/Smad2tm1.1Epb
Smad3tm1Cxd/Smad3tm1Cxd
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * DBA * SJL
|
abnormal cell morphology |
J:119642
|
|
abnormal cell physiology |
J:119642
|
|
increased physiological sensitivity to xenobiotic |
J:119642
|
|
normal
liver/biliary system phenotype |
J:119642
|
Smad2tm1.1Epb/Smad2tm1.1Epb
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129/Sv * C57BL/6 * DBA * SJL
|
abnormal cell differentiation |
J:119642
|
|
abnormal cell migration |
J:119642
|
|
abnormal hepatocyte morphology |
J:119642
|
|
abnormal hepatocyte physiology |
J:119642
|
|
increased hepatocyte proliferation |
J:119642
|
|
normal
liver/biliary system phenotype |
J:119642
|
Smarcd1tm1.1Jddl/Smarcd1tm1.1Jddl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
abnormal feces composition |
J:228944
|
|
decreased bile salt level |
J:228944
|
|
decreased circulating alanine transaminase level |
J:228944
|
|
decreased circulating aspartate transaminase level |
J:228944
|
|
decreased circulating cholesterol level |
J:228944
|
|
decreased circulating HDL cholesterol level |
J:228944
|
|
decreased circulating LDL cholesterol level |
J:228944
|
|
decreased circulating VLDL cholesterol level |
J:228944
|
|
decreased intestinal cholesterol absorption |
J:228944
|
|
increased cholesterol level |
J:228944
|
|
increased liver cholesterol level |
J:228944
|
Soat2tm1.1Llr/Soat2tm1.1Llr
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * DBA
|
decreased circulating cholesterol level |
J:184908
|
|
decreased circulating LDL cholesterol level |
J:184908
|
|
decreased circulating VLDL cholesterol level |
J:184908
|
|
decreased liver cholesterol level |
J:184908
|
|
decreased liver triglyceride level |
J:184908
|
|
normal
digestive/alimentary phenotype |
J:184908
|
|
increased circulating triglyceride level |
J:184908
|
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tspotm1.1Maf/Tspotm1.1Maf
involves: C57BL/6 * DBA
|
normal
liver/biliary system phenotype |
J:214129
|
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Trmutm1Tomik/Trmutm1Tomik
involves: C57BL/6 * DBA
|
abnormal hepatocyte mitochondrial morphology |
J:235644
|
|
abnormal homeostasis |
J:235644
|
|
abnormal inflammatory response |
J:235644
|
|
abnormal mitochondrial crista morphology |
J:235644
|
|
abnormal mitochondrial physiology |
J:235644
|
|
abnormal nucleotide metabolism |
J:235644
|
|
abnormal tricarboxylic acid cycle |
J:235644
|
|
decreased circulating amylase level |
J:235644
|
|
decreased circulating calcium level |
J:235644
|
|
decreased circulating cholesterol level |
J:235644
|
|
decreased circulating creatinine level |
J:235644
|
|
decreased circulating HDL cholesterol level |
J:235644
|
|
decreased circulating serum albumin level |
J:235644
|
|
hepatic necrosis |
J:235644
|
|
normal
homeostasis/metabolism phenotype |
J:235644
|
|
increased cell nucleus count |
J:235644
|
|
increased circulating alanine transaminase level |
J:235644
|
|
increased circulating aspartate transaminase level |
J:235644
|
|
increased circulating lactate dehydrogenase level |
J:235644
|
|
increased circulating lactate level |
J:235644
|
|
increased hepatocyte karyomegaly |
J:235644
|
|
increased mitochondrial DNA content |
J:235644
|
|
increased mitochondrial size |
J:235644
|
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(CAG-cat,-Creg1)#Yal/0
involves: C57BL/6J * DBA
|
abnormal circulating enzyme level |
J:263073
|
|
abnormal glucose homeostasis |
J:263073
|
|
abnormal lipid homeostasis |
J:263073
|
|
decreased circulating alanine transaminase level |
J:263073
|
|
decreased circulating alkaline phosphatase level |
J:263073
|
|
decreased circulating aspartate transaminase level |
J:263073
|
|
decreased circulating glucose level |
J:263073
|
|
decreased circulating insulin level |
J:263073
|
|
decreased liver cholesterol level |
J:263073
|
|
decreased liver free fatty acids level |
J:263073
|
|
decreased liver triglyceride level |
J:263073
|
|
decreased liver weight |
J:263073
|
|
impaired glucose tolerance |
J:263073
|
|
increased liver glycogen level |
J:263073
|
|
insulin resistance |
J:263073
|
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(CAG-Dusp26)#Jhxia/0
involves: C57BL/6 * DBA
|
decreased liver cholesterol level |
J:279111
|
|
decreased liver free fatty acids level |
J:279111
|
|
decreased liver triglyceride level |
J:279111
|
|
decreased liver weight |
J:279111
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:279111
|
|
decreased susceptibility to diet-induced obesity |
J:279111
|
|
impaired glucose tolerance |
J:279111
|
|
increased circulating alanine transaminase level |
J:279111
|
|
increased circulating aspartate transaminase level |
J:279111
|
|
insulin resistance |
J:279111
|
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tor1aip1tm1.1Wtd/Tor1aip1tm1.1Wtd
Not Specified
|
abnormal hepatocyte morphology |
J:345574
|
Sqstm1tm2.1Jmos/Sqstm1tm2.1Jmos
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
normal
behavior/neurological phenotype |
J:194291
|
|
normal
growth/size/body region phenotype |
J:194291
|
|
normal
homeostasis/metabolism phenotype |
J:194291
|
|
normal
liver/biliary system phenotype |
J:194291
|
Srebf2tm1Jdh/Srebf2tm1Jdh
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: 129S6/SvEvTac * C57BL/6 * DBA
|
abnormal lipid homeostasis |
J:241873
|
|
decreased body weight |
J:241873
|
|
decreased circulating cholesterol level |
J:241873
|
|
decreased circulating triglyceride level |
J:241873
|
|
decreased liver cholesterol level |
J:241873
|
|
decreased liver triglyceride level |
J:241873
|
Srsf3tm1Pjln/Srsf3tm1Pjln
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: BALB/c * C57BL/6 * DBA
|
abnormal bile canaliculus morphology |
J:205756
|
|
abnormal endoplasmic reticulum morphology |
J:205756
|
|
abnormal glucose tolerance |
J:205756
|
|
abnormal hepatobiliary system development |
J:205756
|
|
abnormal hepatocyte morphology |
J:205756
|
|
abnormal kidney development |
J:205756
|
|
abnormal liver morphology |
J:205756
|
|
abnormal liver sinusoid morphology |
J:205756
|
|
abnormal thymus development |
J:205756
|
|
decreased body size |
J:205756
|
|
decreased brown adipose tissue amount |
J:205756
|
|
decreased circulating cholesterol level |
J:205756
|
|
decreased circulating HDL cholesterol level |
J:205756
|
|
decreased circulating insulin-like growth factor I level |
J:205756
|
|
decreased circulating serum albumin level |
J:205756
|
|
decreased circulating triglyceride level |
J:205756
|
|
decreased fatty acid oxidation |
J:205756
|
|
decreased liver cholesterol level |
J:205756
|
|
decreased liver glycogen level |
J:205756
|
|
decreased liver triglyceride level |
J:205756
|
|
decreased susceptibility to diet-induced obesity |
J:205756
|
|
hypoglycemia |
J:205756
|
|
increased circulating alanine transaminase level |
J:205756
|
|
increased circulating alkaline phosphatase level |
J:205756
|
|
increased circulating aspartate transaminase level |
J:205756
|
|
increased circulating bilirubin level |
J:205756
|
|
increased circulating growth hormone level |
J:205756
|
|
increased hepatocyte apoptosis |
J:205756
|
|
increased insulin sensitivity |
J:205756
|
|
pale liver |
J:205756
|
|
perinatal lethality, incomplete penetrance |
J:205756
|
|
postnatal lethality, incomplete penetrance |
J:205756
|
|
small liver |
J:205756
|
Ssu72tm1Cwl/Ssu72tm1Cwl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
B6.Cg-Ssu72tm1Cwl Speer6-ps1Tg(Alb-cre)21Mgn
|
abnormal hepatocyte morphology |
J:309624
|
|
abnormal Ito cell morphology |
J:309624
|
|
abnormal liver development |
J:309624
|
|
abnormal liver morphology |
J:309624
|
|
hepatic necrosis |
J:309624
|
|
hepatic steatosis |
J:309624
|
|
increased circulating alanine transaminase level |
J:309624
|
|
increased circulating aspartate transaminase level |
J:309624
|
|
increased hepatocyte apoptosis |
J:309624
|
|
increased hepatocyte karyomegaly |
J:309624
|
|
increased hepatocyte proliferation |
J:309624
|
|
increased liver weight |
J:309624
|
|
increased physiological sensitivity to xenobiotic |
J:309624
|
|
liver fibrosis |
J:309624
|
|
liver inflammation |
J:309624
|
|
normal
neoplasm |
J:309624
|
Stat3tm1Vpo/Stat3tm1Vpo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
increased incidence of tumors by chemical induction |
J:172422
|
Stk3tm1.1Rjo/Stk3tm1.1Rjo
Stk4tm1.1Rjo/Stk4tm1.1Rjo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL
|
abnormal hepatocyte morphology |
J:156531
|
|
abnormal liver morphology |
J:156531
|
|
abnormal liver sinusoid morphology |
J:156531
|
|
normal
homeostasis/metabolism phenotype |
J:156531
|
|
increased hepatocellular carcinoma incidence |
J:156531
|
|
increased hepatocyte apoptosis |
J:156531
|
|
increased hepatocyte proliferation |
J:156531
|
|
increased liver tumor incidence |
J:156531
|
|
increased liver weight |
J:156531
|
Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * CBA * DBA
|
abnormal hepatocyte morphology |
J:156541
|
|
abnormal liver morphology |
J:156541
|
|
enlarged liver |
J:156541
|
|
increased hepatocyte apoptosis |
J:156541
|
|
increased hepatocyte proliferation |
J:156541
|
Stk3tm1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * 129P2/OlaHsd * C57BL/6 * DBA
|
increased hepatocellular carcinoma incidence |
J:238319
|
Stk3tm1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6
|
increased hepatocellular carcinoma incidence |
J:153945
|
|
liver hyperplasia |
J:153945
|
Thrap3tm1c(KOMP)Wtsi/Thrap3tm1c(KOMP)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA
|
abnormal autophagosome formation |
J:339439
|
|
abnormal hepatocyte physiology |
J:339439
|
|
abnormal liver physiology |
J:339439
|
|
abnormal mitochondrial ATP synthesis coupled electron transport |
J:339439
|
|
abnormal mitochondrial crista morphology |
J:339439
|
|
abnormal mitophagy |
J:339439
|
|
abnormal respiratory electron transport chain |
J:339439
|
|
decreased body weight |
J:339439
|
|
decreased circulating alanine transaminase level |
J:339439
|
|
decreased circulating aspartate transaminase level |
J:339439
|
|
decreased circulating cholesterol level |
J:339439
|
|
decreased circulating free fatty acids level |
J:339439
|
|
decreased circulating glucose level |
J:339439
|
|
decreased circulating insulin level |
J:339439
|
|
decreased circulating triglyceride level |
J:339439
|
|
decreased liver cholesterol level |
J:339439
|
|
decreased liver triglyceride level |
J:339439
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:339439
|
|
enhanced autophagy |
J:339439
|
|
improved glucose tolerance |
J:339439
|
|
increased energy expenditure |
J:339439
|
|
increased hepatocyte mitochondrial DNA content |
J:339439
|
|
increased insulin sensitivity |
J:339439
|
|
increased mitochondrial size |
J:339439
|
|
increased oxygen consumption |
J:339439
|
Tjp1tm1.1Whun/Tjp1tm1.1Whun
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * C57BL/6NTac * DBA/2
|
normal
liver/biliary system phenotype |
J:306936
|
Tjp1tm1.1Whun/Tjp1tm1.1Whun
Tjp2tm2Whun/Tjp2tm2Whun
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6N * C57BL/6NTac * DBA/2
|
abnormal bile canaliculus morphology |
J:306936
|
|
abnormal hepatic cord morphology |
J:306936
|
|
abnormal hepatic duct morphology |
J:306936
|
|
abnormal hepatocyte morphology |
J:306936
|
|
abnormal liver morphology |
J:306936
|
|
abnormal liver physiology |
J:306936
|
|
abnormal liver sinusoid morphology |
J:306936
|
|
increased bile salt level |
J:306936
|
|
increased circulating alanine transaminase level |
J:306936
|
|
increased circulating alkaline phosphatase level |
J:306936
|
|
increased circulating aspartate transaminase level |
J:306936
|
|
increased circulating bilirubin level |
J:306936
|
|
increased circulating LDL cholesterol level |
J:306936
|
|
increased hepatocyte proliferation |
J:306936
|
|
increased liver weight |
J:306936
|
|
postnatal lethality, incomplete penetrance |
J:306936
|
|
premature death |
J:306936
|
|
small liver |
J:306936
|
Tjp2tm2Whun/Tjp2tm2Whun
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac * DBA/2
|
increased circulating alanine transaminase level |
J:306936
|
|
increased circulating aspartate transaminase level |
J:306936
|
|
increased circulating LDL cholesterol level |
J:306936
|
|
normal
liver/biliary system phenotype |
J:306936
|
Tmem30atm1.1Xjz/Tmem30atm1.1Xjz
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6J * DBA
|
abnormal liver morphology |
J:249038
|
|
abnormal spine curvature |
J:249038
|
|
bile duct proliferation |
J:249038
|
|
cachexia |
J:249038
|
|
decreased liver weight |
J:249038
|
|
normal
growth/size/body region phenotype |
J:249038
|
|
normal
homeostasis/metabolism phenotype |
J:249038
|
|
increased alkaline phosphatase activity |
J:249038
|
|
increased bile salt level |
J:249038
|
|
increased circulating alanine transaminase level |
J:249038
|
|
increased circulating aspartate transaminase level |
J:249038
|
|
increased circulating bilirubin level |
J:249038
|
|
intrahepatic cholestasis |
J:249038
|
|
jaundice |
J:249038
|
|
liver fibrosis |
J:249038
|
|
liver inflammation |
J:249038
|
|
slow movement |
J:249038
|
Tor1atm3.1Wtd/Tor1a+
Tor1aip1tm1.1Wtd/Tor1aip1tm1.1Wtd
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA
|
abnormal hepatocyte morphology |
J:345574
|
|
hepatic steatosis |
J:345574
|
Tor1atm3.1Wtd/Tor1atm3.1Wtd
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA
|
hepatic steatosis |
J:345574
|
Tor1atm3.1Wtd/Tor1atm3.1Wtd
Tor1aip1tm1.1Wtd/Tor1aip1+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA
|
hepatic steatosis |
J:345574
|
Tor1atm3.1Wtd/Tor1atm3.1Wtd
Tor1aip1tm1.1Wtd/Tor1aip1tm1.1Wtd
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA
|
abnormal hepatocyte morphology |
J:345574
|
|
abnormal liver physiology |
J:345574
|
|
hepatic steatosis |
J:345574
|
Tor1aip2tm1.1Wtd/Tor1aip2tm1.1Wtd
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6J * DBA
|
normal
liver/biliary system phenotype |
J:345574
|
|
no abnormal phenotype detected |
J:345574
|
Trnau1aptm2.1Usch/Trnau1aptm2.1Usch
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
normal
homeostasis/metabolism phenotype |
J:237714
|
Tsc1tm1Djk/Tsc1tm1Djk
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:171445
|
|
abnormal hepatocyte physiology |
J:171445
|
|
abnormal homeostasis |
J:171445
|
|
decreased circulating triglyceride level |
J:171445
|
|
enlarged liver |
J:171445
|
|
impaired glucose tolerance |
J:171445
|
|
insulin resistance |
J:171445
|
|
normal
liver/biliary system phenotype |
J:171445
|
Txniptm1Road/Txniptm1Road
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA
|
normal
growth/size/body region phenotype |
J:132756
|
|
normal
homeostasis/metabolism phenotype |
J:132756
|
|
normal
mortality/aging |
J:132756
|
|
normal
reproductive system phenotype |
J:132756
|
Uqcc3em1Hya/Uqcc3em1Hya
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA/2
|
abnormal mitochondrial morphology |
J:306534
|
|
abnormal physiological response to hypoxia |
J:306534
|
|
decreased incidence of induced tumors |
J:306534
|
|
normal
liver/biliary system phenotype |
J:306534
|
Usp20em1Gpt/Usp20em1Gpt
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6JGpt * DBA
|
abnormal circulating enzyme level |
J:299971
|
|
abnormal enzyme/coenzyme level |
J:299971
|
|
abnormal liver morphology |
J:299971
|
|
normal
behavior/neurological phenotype |
J:299971
|
|
decreased body fat mass |
J:299971
|
|
decreased body weight |
J:299971
|
|
decreased circulating cholesterol level |
J:299971
|
|
decreased circulating free fatty acids level |
J:299971
|
|
decreased circulating glucose level |
J:299971
|
|
decreased circulating HDL cholesterol level |
J:299971
|
|
decreased circulating insulin level |
J:299971
|
|
decreased circulating LDL cholesterol level |
J:299971
|
|
decreased circulating triglyceride level |
J:299971
|
|
decreased circulating VLDL triglyceride level |
J:299971
|
|
decreased fasting circulating glucose level |
J:299971
|
|
decreased fat cell size |
J:299971
|
|
decreased liver cholesterol level |
J:299971
|
|
decreased liver triglyceride level |
J:299971
|
|
decreased liver weight |
J:299971
|
|
decreased white adipose tissue mass |
J:299971
|
|
normal
homeostasis/metabolism phenotype |
J:299971
|
|
improved glucose tolerance |
J:299971
|
|
increased body surface temperature |
J:299971
|
|
increased energy expenditure |
J:299971
|
|
increased insulin sensitivity |
J:299971
|
|
increased oxygen consumption |
J:299971
|
Vhltm1Jae/Vhltm1Jae
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA
|
abnormal blood vessel morphology |
J:67505
|
|
abnormal liver morphology |
J:67505
|
|
abnormal vasodilation |
J:97652
|
|
decreased body weight |
J:67505
|
|
enlarged liver |
J:67505
|
|
hepatic steatosis |
J:67505,
J:97652
|
|
increased vascular endothelial cell number |
J:97652
|
|
polycythemia |
J:67505
|
|
premature death |
J:67505
|
Vhltm1Jae/Vhltm1Jae
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
|
abnormal blood vessel morphology |
J:144666
|
|
abnormal hepatocyte morphology |
J:144666
|
|
abnormal liver morphology |
J:144666
|
|
decreased body size |
J:144666
|
|
hepatic steatosis |
J:144666
|
|
increased hematocrit |
J:144666
|
|
increased hepatocyte proliferation |
J:144666
|
|
increased liver weight |
J:144666
|
|
premature death |
J:144666
|
|
reddish skin |
J:144666
|
|
reticulocytosis |
J:144666
|
Wwc1tm1Arsc/Wwc1tm1Arsc
Wwc2tm1.1Arte/Wwc2tm1.1Arte
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6 * C57BL/6J * DBA
|
abnormal liver morphology |
J:305034
|
|
abnormal liver physiology |
J:305034
|
|
abnormal portal triad morphology |
J:305034
|
|
increased liver tumor incidence |
J:305034
|
|
increased liver weight |
J:305034
|
|
liver fibrosis |
J:305034
|
|
liver inflammation |
J:305034
|
Wwc2tm1.1Arte/Wwc2tm1.1Arte
Speer6-ps1Tg(Alb-cre)21Mgn/0
involves: C57BL/6 * DBA
|
normal
liver/biliary system phenotype |
J:305034
|
Yap1tm1.1Dupa/Yap1tm1.1Dupa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
abnormal bile duct development |
J:162628
|
|
abnormal bile duct morphology |
J:162628
|
|
abnormal hepatocyte morphology |
J:162628
|
|
enlarged liver |
J:162628
|
|
increased circulating alanine transaminase level |
J:162628
|
|
increased circulating bilirubin level |
J:162628
|
|
increased hepatocyte apoptosis |
J:162628
|
|
increased hepatocyte proliferation |
J:162628
|
|
liver cirrhosis |
J:162628
|
|
liver fibrosis |
J:162628
|
|
macrovesicular hepatic steatosis |
J:162628
|
|
pale liver |
J:162628
|
Zbtb20tm1Wpjz/Zbtb20tm1Wpjz
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL * C57BL/6 * DBA
|
normal
liver/biliary system phenotype |
J:140053
|
Zc3h12atm1c(EUCOMM)Hmgu/Zc3h12atm1c(EUCOMM)Hmgu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * C57BL/6N * DBA
|
abnormal bile duct epithelium morphology |
J:304105
|
|
abnormal bile duct physiology |
J:304105
|
|
abnormal liver parenchyma morphology |
J:304105
|
|
bile duct hyperplasia |
J:304105
|
|
bile duct inflammation |
J:304105
|
|
enlarged liver |
J:304105
|
|
enlarged spleen |
J:304105
|
|
granulomatous inflammation |
J:304105
|
|
increased anti-nuclear antigen antibody level |
J:304105
|
|
increased autoantibody level |
J:304105
|
|
increased bile salt level |
J:304105
|
|
increased circulating alkaline phosphatase level |
J:304105
|
|
increased IgG level |
J:304105
|
|
increased IgM level |
J:304105
|
|
intrahepatic cholestasis |
J:304105
|
|
liver fibrosis |
J:304105
|
|
liver inflammation |
J:304105
|
Excel File
Analysis Tools